Institutes
Refine
Year of publication
- 2021 (662) (remove)
Document Type
- Article (613)
- Preprint (32)
- Conference Proceeding (11)
- Doctoral Thesis (6)
Language
- English (662) (remove)
Has Fulltext
- yes (662) (remove)
Is part of the Bibliography
- no (662)
Keywords
- SARS-CoV-2 (23)
- COVID-19 (20)
- inflammation (12)
- prostate cancer (9)
- autophagy (8)
- Epilepsy (7)
- survival (7)
- ADHD (6)
- breast cancer (6)
- radical prostatectomy (6)
- tumor microenvironment (6)
- Genetics (5)
- aging (5)
- apoptosis (5)
- children (5)
- endothelial cells (5)
- mortality (5)
- outcome (5)
- risk factors (5)
- Cancer (4)
- Heart failure (4)
- Immunotherapy (4)
- Neurology (4)
- ROS (4)
- Risk factors (4)
- acute myeloid leukemia (4)
- angiogenesis (4)
- chemotherapy (4)
- epilepsy (4)
- extracellular matrix (4)
- gene therapy (4)
- hypoxia (4)
- iron (4)
- iron deficiency (4)
- oxidative stress (4)
- prevalence (4)
- stroke (4)
- targeted therapy (4)
- vaccination (4)
- 177Lu-PSMA-617 (3)
- Acute myeloid leukemia (3)
- Alcohol (3)
- Angiogenesis (3)
- Apoptosis (3)
- Biochemistry (3)
- Bipolar disorder (3)
- Cell biology (3)
- Diagnostic markers (3)
- EEG (3)
- Edema (3)
- Immunology (3)
- IntelliCage (3)
- Medical research (3)
- Melanoma (3)
- Microbiology (3)
- Molecular biology (3)
- Mortality (3)
- NK cells (3)
- Outcome (3)
- PSMA (3)
- Proteomics (3)
- Quality of life (3)
- Radiotherapy (3)
- Seizure (3)
- Surgery (3)
- Survival (3)
- VEGF (3)
- adverse events (3)
- biomarker (3)
- bladder cancer (3)
- cancer (3)
- cirrhosis (3)
- data science (3)
- dentate gyrus (3)
- epidemiology (3)
- exosomes (3)
- external beam radiotherapy (3)
- fMRI (3)
- glioblastoma (3)
- haemophilia care (3)
- haemophilia treatment (3)
- immune cells (3)
- immunotherapy (3)
- influenza (3)
- liver (3)
- liver cirrhosis (3)
- lung cancer (3)
- macrophage polarization (3)
- macrophages (3)
- metastasis (3)
- metastatic prostate cancer (3)
- pediatric (3)
- proliferation (3)
- toll-like receptor (3)
- treatment (3)
- treatment centres (3)
- 3D printing (2)
- ALK (2)
- Acuris (2)
- Acute lymphoblastic leukemia (2)
- Adenocarcinoma (2)
- Age estimation (2)
- Anemia (2)
- Angiography (2)
- Ataxia-telangiectasia (2)
- Attitude (2)
- Autopsy (2)
- BAG3 (2)
- BCOR (2)
- BPH (2)
- Bacterial infection (2)
- Behavior (2)
- Blood (2)
- Blood loss estimation (2)
- Blow flies (2)
- Bone density (2)
- Bone marrow (2)
- Brain (2)
- Breast cancer (2)
- Burden of illness (2)
- CD14 (2)
- COVID 19 (2)
- CRM (2)
- CSM (2)
- Cancer-specific mortality (2)
- Cardiovascular diseases (2)
- Cell culture (2)
- Cesarean section (2)
- Chronic kidney disease (2)
- Cirrhosis (2)
- Collagen (2)
- Corona (2)
- DMEK (2)
- Dental implant (2)
- Depression (2)
- Dravet syndrome (2)
- ER stress (2)
- EWSR1 (2)
- Endocannabinoid (2)
- Endocrinology (2)
- Entscheidungsassistenz (2)
- Environmental support (2)
- Epidemiology and End Results (2)
- Fasting (2)
- Forensic medicine (2)
- Gene fusion (2)
- Gene regulation (2)
- Gleason score (2)
- Glioblastoma (2)
- Glucose (2)
- Health care (2)
- Healthcare costs (2)
- Human behaviour (2)
- Hypertension (2)
- Induction chemotherapy (2)
- Infection (2)
- Inflammation (2)
- Intensive care treatment (2)
- Intensive care units (2)
- Interleukin-6 (2)
- Ketogenic diet (2)
- Labor and delivery (2)
- Leptin (2)
- MRI (2)
- Machine learning (2)
- Medical consultation (2)
- Medical risk factors (2)
- Model (2)
- Multidetector computed tomography (2)
- NADH dehydrogenase (2)
- NADPH oxidase (2)
- NCCN (2)
- NF-κB (2)
- Neuroscience (2)
- Osteoporosis (2)
- PCR (2)
- Pandemic (2)
- Pathogenesis (2)
- Patient blood management (2)
- Patient needs (2)
- Patientenbedürfnisse (2)
- Pediatric (2)
- Penile cancer (2)
- Periodontal treatment (2)
- Person-Umwelt-Passung (2)
- Person-environment fit (2)
- Physical activity (2)
- Physiology (2)
- Platelet-rich fibrin (2)
- Point-of-care testing (2)
- Portal hypertension (2)
- Post-mortem interval (2)
- Pregnancy (2)
- Preterm birth (2)
- Prevalence (2)
- Prognostic tool (2)
- Prophylaxis (2)
- Prostate cancer (2)
- Pulmonary embolism (2)
- Radiation (2)
- Rare diseases (2)
- Research Article (2)
- SCC (2)
- SV2A (2)
- Sensitivity (2)
- Specificity (2)
- Spine (2)
- Squamous cell carcinoma (2)
- Status epilepticus (2)
- Suicide (2)
- Supported decision making (2)
- Surveillance (2)
- Systemic inflammation (2)
- Systemic therapy (2)
- TSC (2)
- Tomography (x-ray computed) (2)
- Tooth loss (2)
- Trauma (2)
- Treatment (2)
- Treatment outcome (2)
- Ultrasound (2)
- Undergraduate medical education (2)
- Unterstützung der Umwelt (2)
- Usability (2)
- Variant histology (2)
- Visual estimation (2)
- alcohol use disorder (2)
- anemia (2)
- animal experiments (2)
- antibiotic resistance (2)
- antiviral therapy (2)
- bibliometrics (2)
- biomarkers (2)
- biopsy cores (2)
- bleeding (2)
- bortezomib (2)
- brain cancer (2)
- cancer-specific mortality (2)
- cell cycle (2)
- cell migration (2)
- cerebrospinal fluid (2)
- cesarean section (2)
- child (2)
- childhood acute myeloid leukemia (2)
- chronic kidney disease (2)
- clinical trial (2)
- clinical trials (2)
- colon cancer (2)
- complexome profiling (2)
- computed tomography (2)
- contemporary (2)
- coronavirus (2)
- critical care (2)
- dexamethasone (2)
- diabetes (2)
- diabetes mellitus (2)
- diagnostic algorithm (2)
- drug resistance (2)
- efficacy (2)
- elderly (2)
- electrophysiology (2)
- epigenetics (2)
- epithelial to mesenchymal transition (2)
- ergonomics (2)
- executive function (2)
- extracellular vesicles (2)
- fibroblasts (2)
- follow-up (2)
- furcation involvement class III (2)
- fusion biopsy (2)
- heart (2)
- heart failure (2)
- hematopoietic stem cell transplantation (2)
- homeostatic plasticity (2)
- innate immunity (2)
- intermediate risk (2)
- iron metabolism (2)
- kidney (2)
- kidney cancer (2)
- levetiracetam (2)
- lipocalin-2 (2)
- liver transplantation (2)
- lncRNA (2)
- localized prostate cancer (2)
- long-term tooth survival (2)
- lymph node dissection (2)
- machine learning (2)
- macrophage (2)
- magnetic resonance imaging (2)
- mast cells (2)
- metastatic castration-resistant prostate cancer (2)
- miRNA (2)
- microRNA (2)
- microglia (2)
- multiple sclerosis (2)
- ncRNA (2)
- neurocognitive (2)
- neuropathic pain (2)
- neutralizing antibodies (2)
- niche (2)
- oligomerisation (2)
- osteoarthritis (2)
- other-cause mortality (2)
- out-patient paediatrics (2)
- overall survival (2)
- oxidative phosphorylation (2)
- p53 (2)
- pain (2)
- patients (2)
- pediatric patients (2)
- pentose phosphate pathway (2)
- perception (2)
- periodontitis stage III and IV (2)
- pharmacokinetics (2)
- phosphorylation (2)
- platelets (2)
- pneumonia (2)
- portal hypertension (2)
- primary care (2)
- primary cilium (2)
- primary prostate cancer (2)
- questionnaire (2)
- radical prostatecomy (2)
- radiotherapy (2)
- receptor (2)
- refractory (2)
- regenerative medicine (2)
- relapse (2)
- residual myometrial thickness (2)
- respiratory chain (2)
- respiratory tract infection (2)
- salvage therapy (2)
- second-line (2)
- seizure (2)
- spine head (2)
- status epilepticus (2)
- strength training (2)
- stress (2)
- stress granules (2)
- supportive periodontal therapy (2)
- surgery (2)
- synaptic plasticity (2)
- synaptopodin (2)
- systematic biopsy (2)
- systemic antibiotics (2)
- thrombolysis (2)
- thrombosis (2)
- tissue engineering (2)
- tooth loss (2)
- triple-negative breast cancer (2)
- tumor necrosis factor (2)
- tumor-associated macrophages (2)
- tyrosine kinase inhibitors (2)
- ubiquitination (2)
- urological cancer (2)
- very high risk (2)
- working memory (2)
- Ärztliche Aufklärung (2)
- (sub-) luxation (1)
- 1-propanol (1)
- 2-AG (1)
- 2-Arachidonoyl glycerol (1)
- 2-deoxy-d-glucose (1)
- 26 LncRNA (1)
- 2′,3′-cGAMP (1)
- 3-year survival (1)
- 3D gait analysis (1)
- 3D printing using composite resin (1)
- 3D printing using zirconia (1)
- 3D rapid prototyping (1)
- 3T3-L1 mouse fibroblasts (1)
- 5-lipoxygenase (1)
- ABCB5 (1)
- ACE inhibitor (1)
- ACLF (1)
- ADAM15 (1)
- ADCC (1)
- AGMO (1)
- AIDS (1)
- AKT (1)
- AKT signaling (1)
- ALD (1)
- ALDH2 (1)
- AML (1)
- AO-PCCF (1)
- APT-CEST (1)
- ARDS (1)
- AT1 receptor antagonist (1)
- ATG3 (1)
- AU-rich element (1)
- Accidents (1)
- Acinetobacter baumannii (1)
- Acquired resistance (1)
- Acute Myeloid Leukemia (AML) (1)
- Acute inflammation (1)
- Acute kidney failure (1)
- Acute kidney injury (1)
- Acute respiratory distress syndrom (1)
- Adiposity (1)
- Adults (1)
- Advanced stage (1)
- Adverse effects (1)
- Aedes aegypti (1)
- Aedes albopictus (1)
- Affective Misattribution Procedure (1)
- Ag-RDT (1)
- Aganglionosis (1)
- Aging (1)
- Albumin (1)
- Algorithms (1)
- Alpha power (1)
- Alpha-fetoprotein (AFP) (1)
- Alzheimer's disease (1)
- Amblyopia (1)
- Amino acids (1)
- Amniotic fluid (1)
- Amphetamine (1)
- Analysis tool (1)
- Anandamide (1)
- Anemia management (1)
- Angiomyolipoma (1)
- Angststörungen (1)
- Animal disease models (1)
- Animal experiment (1)
- Animal models (1)
- Anti-seizure medication (1)
- Antibiotic steward-ship (1)
- Antibiotics (1)
- Antibody avidity (1)
- Anticonvulsant (1)
- Antimicrobial treatment (1)
- Antiretroviral therapy (1)
- Anwendbarkeit (1)
- Anxiety (1)
- Apoptotic cell death (1)
- Ara h2-specific IgE (1)
- Artificial intelligence (1)
- Asparaginase (1)
- Aspergillus (1)
- Astrocytoma (1)
- Ataxia telangiectasia (1)
- Atomoxetine (1)
- Attention (1)
- Attention Deficit Hyperactivity Disorder (ADHD) (1)
- Attention-Deficit/Hyperactivity Disorder (ADHD) (1)
- Autism (1)
- Autism Spectrum disorder (1)
- Autism spectrum disorder (1)
- Autologous biomaterial (1)
- Ayurveda (1)
- B cells (1)
- B-cell transcription factors (1)
- B.1.1.7 (1)
- B.1.617.1 (1)
- B.1.617.2 (1)
- BCORL1 (1)
- BCX7353 (1)
- BEACOPP (1)
- BMI (1)
- BMNC (1)
- BNT162b2 (1)
- BNT2b2 (1)
- BPO (1)
- BPTF (1)
- BRD4 (1)
- Back scan (1)
- Bacterial leakage (1)
- Barrier (1)
- Bartonella grahamii (1)
- Bartonella henselae (1)
- Bartonella schoenbuchensis (1)
- Basal ganglia (1)
- Beckwith–Wiedemann syndrome (1)
- Behandlungspfad (1)
- Behavioural ecology (1)
- Berotralstat (1)
- Bevacizumab (1)
- Big Five (1)
- Bio safety (1)
- Biofilm (1)
- Biological profile (1)
- Biomarker (1)
- Biomarkers (1)
- Biophysical models (1)
- Biophysics (1)
- Biopsy (1)
- Birth (1)
- Birth weight (1)
- Bleeding (1)
- Blood coagulation disorder (1)
- Blood loss calculator (1)
- Blood loss formula (1)
- Blood management (1)
- Blood plasma (1)
- Blood sampling (1)
- Blutungskontrolle (1)
- Body sway (1)
- Bone cement implantation syndrome (1)
- Bone diseases, Metabolic (1)
- Bone metastases (1)
- Bowel obstruction (1)
- Bradycardia (1)
- Brain metastasis (1)
- Brain tumor (1)
- Browsertool (1)
- Burkitt’s lymphoma (1)
- C-reactive protein (1)
- C1 inhibitor (1)
- CAD-CAM (1)
- CAD/ CAM crown (1)
- CAD/CAM crown (1)
- CAM (1)
- CAPON (1)
- CCC-2 (1)
- CD16 (1)
- CD34+ cell enumeration (1)
- CD36 (1)
- CD45RA Depletion (1)
- CD47 (1)
- CD62L (1)
- CD8+ T cells (1)
- CDH13 (1)
- CDK2 (1)
- CDK4/6 inhibitors (1)
- CDK9 (1)
- CEST EPI (1)
- CNDAC (1)
- COMP (1)
- COPD (1)
- COVID-19 pandemic (1)
- COVID-19 vaccination (1)
- COVID-19, Primary care (1)
- COVID‐19 (1)
- CRISPR/Cas (1)
- CRPC (1)
- CT (1)
- CT dual-energy computed tomography (1)
- CTLA-4 (1)
- Cabozantinib (1)
- Calcium (1)
- Calcium calmodulin kinase (1)
- Calliphoridae (1)
- Cancer genomics (1)
- Cancer survivors (1)
- Cancer therapy (1)
- Cancer-specific survival (1)
- Cannabis (1)
- Cardiac biomarkers (1)
- Cardiac implantable electronic devices (1)
- Cardiac rehabilitation (1)
- Cardiac resynchronization therapy (1)
- Cardio-oncology (1)
- Cardiotoxicity (1)
- Cardiovascular biology (1)
- Cardiovascular disease risk (1)
- Cardiovascular magnetic resonance (1)
- Carotid injury (1)
- Case report (1)
- Catumaxomab (1)
- Cell death (1)
- Cell division (1)
- Cell-based Assays (1)
- Cement gap (1)
- Ceramides (1)
- Checkpoint Inhibitor (1)
- Chikungunya (1)
- Chimeric Antigen Receptor (CAR) (1)
- Cholinergic (1)
- Chrna7 knockout (1)
- Circadian (1)
- Clinical Global Impression of Change (1)
- Clinical Trials and Observations (1)
- Clinical decision support systems (1)
- Clinical pathway (1)
- Clinical pharmacology (1)
- ClpB (1)
- Cochlear implantation (1)
- Cognitive dysfunction (1)
- Cohort studies (1)
- Colorectal cancer (1)
- Colorimetric blood loss estimation (1)
- Combined surgical therapy (1)
- Combustion (1)
- Complex decongestive therapy (1)
- Complicated stage (1)
- Complications (1)
- Computational models (1)
- Computational neuroscience (1)
- Computational science (1)
- Computed tomography, X-ray (1)
- Computer hardware (1)
- Computer science (1)
- Computer software (1)
- Computer-assisted diagnosis (1)
- Cone-beam computed tomography (1)
- Conometric connection (1)
- Consensus document (1)
- Constipation (1)
- Contingent Negative Variation, CNV (1)
- Continuous Performance Test, CPT (1)
- Continuous renal replacement therapy (1)
- Contrast agent (1)
- Corneal tomography (1)
- Corona virus (1)
- Coronary heart disease (1)
- Costs (1)
- Course (1)
- Covid-19 (1)
- Cre-recombinase (1)
- Crisis (1)
- Critical care (1)
- Cue-P3 (1)
- Culicidae (1)
- Custom-made mouthguard (1)
- Cyclin T1 (1)
- Cystatin C (1)
- DC-NK cell interaction (1)
- DCK (1)
- DNA integrity (1)
- DPPIV (1)
- Data Analysis (1)
- Data processing (1)
- Data reduction (1)
- Daubert criteria (1)
- Dead space (1)
- Decision support (1)
- Deep brain stimulation (1)
- Degradation (1)
- Dengue (1)
- Dentists (1)
- Developmental Biology (1)
- Dexamethasone (1)
- Diagnosis (1)
- Diagnostic algorithm (1)
- Diffusion magnetic resonance imaging (1)
- Diphtheria (1)
- Diptera (1)
- Direct measurement (1)
- Direct oral anticoagulation (1)
- Disease progression (1)
- Diseases (1)
- Dislocations of the knee (1)
- Dizygotic ectopic (1)
- Dopamine (1)
- Dose response (1)
- Droplets (1)
- Drospirenon (1)
- Drug addiction (1)
- Drug resistance (1)
- Drug targets (1)
- Drug therapy (1)
- Dual-energy computed tomography (1)
- Dynamic MRI (1)
- Dysfunctional social assumptions (1)
- D’Amico classification (1)
- EBRT (1)
- ECMO (1)
- EET (1)
- EHL concentrates (1)
- ENIGMA (1)
- EP300 (1)
- EQ5D5L (1)
- EQA scheme (1)
- ER-phagy (1)
- ERAL1 (1)
- ERK inhibitor (1)
- ERK1/2 signaling (1)
- ESBL (1)
- Early setting (1)
- Eccentric fixation (1)
- Ectopic pregnancy (1)
- Effective half-life (1)
- Efficacy (1)
- Efficiency (1)
- Electric stimulation (1)
- Elternurteil (1)
- Emergency room (1)
- Ena/VASP proteins (1)
- Encephalopathy (1)
- Endocrine system and metabolic diseases (1)
- Endocrine therapy (1)
- Endothelial cells (1)
- Endothelial progenitor cells (1)
- Energy (1)
- Engraftment (1)
- Enterobacterales (1)
- Environmental biotechnology (1)
- Environmental sciences (1)
- EpCAM positive tumor (1)
- Ephrin-B2–EphB4 (1)
- Epigenetics (1)
- Epileptische Anfälle (1)
- Epileptischer Anfall (1)
- Epithelialization (1)
- Epsilon (1)
- Estimated glomerular filtration rate (1)
- Event related potentials (1)
- Everolimus (1)
- Evidence-based (1)
- Evidenzbasiert (1)
- Ewing sarcoma (1)
- Ewing-like (1)
- Exercise (1)
- Exercise training (1)
- Exoscope (1)
- Exosomes (1)
- Expansion (1)
- Expectation violation (1)
- External beam radiotherapy (1)
- Extracellular matrix (1)
- Extracellular vesicles (1)
- Exudates and transudates (1)
- FABP (1)
- FAM134 (1)
- FFP3 respirator (1)
- FGFR (1)
- FOXO1 (1)
- FOXO3 (1)
- FXR (1)
- Facial nerve (1)
- Falls (1)
- Feasibility studies (1)
- Fendrr (1)
- Fertility counseling (1)
- Filariasis (1)
- Fluid overload (1)
- Fluorescence (1)
- Forensic entomology (1)
- Forensic experts (1)
- Forensic pathology (1)
- Frontobasal (1)
- Fuchs endothelial dystrophy (1)
- G2A (1)
- GD2 (1)
- GEMs (1)
- GFR (1)
- GIIb/IIIa-receptor (1)
- GMP (1)
- GPCR (1)
- GPR4 (1)
- GTP cyclohydrolase (1)
- Ganglionic (1)
- Gan–Dou–Fu–Mu decoction (GDFMD) (1)
- Gastric motility (1)
- Gastroenterology (1)
- Gender (1)
- Gene expression (1)
- General Practitioner (1)
- Genetic techniques (1)
- Genetics research (1)
- Genome editing (1)
- Gestagen-Monopräparate (1)
- Gezielte Therapie (1)
- Glaucoma (1)
- Gleason Grade Group (1)
- Gleason grade group (1)
- Glioblastoma survival (1)
- Glomerulosclerosis (1)
- Glycolysis (1)
- Grading (1)
- Graft (1)
- Graft quality (1)
- Granulocytes (1)
- Graves’ disease (1)
- Gravimetric method (1)
- Guidance (1)
- Guide profession (1)
- Gut (1)
- H1N1 (1)
- HAE (1)
- HARS2 (1)
- HBV (1)
- HCC (1)
- HCC marker (1)
- HDR-brachytherapy (1)
- HER2 (1)
- HIV (1)
- HIV protease inhibitors (1)
- HL7 FHIR (1)
- HLA antibodies (1)
- HNSCC (1)
- HOLEP (1)
- HOTAIR (1)
- HPO (1)
- HPV-positive OPSCC (1)
- HRCT (1)
- HSC (1)
- HSP (hereditary spastic paraplegia) (1)
- HVPG (1)
- Haematologic diseases (1)
- Haemophilia (1)
- HeLa cells (1)
- Head and neck cancer (1)
- Health care workers (1)
- Health services (1)
- Health surveys (1)
- Healthcare resource utilisation (1)
- Healthcare resource utilization (1)
- Healthy adults (1)
- Healthy men (1)
- Heart (1)
- Heart transplantation (1)
- Heartrate (1)
- Hematologic adverse events (1)
- Hematopoietic stem cell (1)
- Hematotoxicity (1)
- Hepatic stellate cell (1)
- Hepatocellular carcinoma (1)
- Hepatocellular carcinoma (HCC) (1)
- Hereditary angioedema (1)
- Herniated disk (1)
- Heterotopic pregnancy (1)
- Hierarchical drift-diffusion modeling (1)
- High altitude (1)
- High-risk prostate cancer (1)
- Himalayas (1)
- Hip hemiarthroplasty (1)
- Hirschsprung disease (1)
- Hispanic–Latino race/ethnicity (1)
- Histology (1)
- HoLEP (1)
- Hormone receptor positive breast cancer (1)
- Hydromineral (1)
- Hymenoptera venom allergy (1)
- IAP (1)
- ICG (1)
- IFN-β (1)
- IL-17A (1)
- IL-1b (1)
- IL-33 (1)
- INR (1)
- IPSS (1)
- ISR (1)
- IgA deficiency (1)
- Ileostomy (1)
- Ileus (1)
- Image processing (1)
- Immune cells (1)
- Immune checkpoint inhibitors (1)
- Immune complex vasculitis (1)
- Immune paralysis (1)
- Immune status (1)
- Immunodeficiency (1)
- Immunogenetics (1)
- Immunoglobulins (1)
- Immunohistochemistry (1)
- Immunophenotyping (1)
- Immuno‑histochemistry (1)
- Implantable cardioverter-defibrillator (1)
- Implicit Processing (1)
- Implicit Association Test (1)
- In vivo electrophysiology (1)
- Inactivation (1)
- IncX (1)
- Incidence rate (1)
- Incontinence (1)
- Indication for fertility preservation (1)
- Indirect treatment comparison (ITC) (1)
- Indocyanine green (1)
- Indonesia (1)
- Injuries (1)
- Injury (1)
- Intention attribution (1)
- Interleukin-10 (1)
- International normalized ratio (1)
- Internet-based therapy (1)
- Interpretation Bias (1)
- Intervention (1)
- Intervertebral disc displacement (1)
- Interviews (1)
- Intimal-medial thickness (1)
- Intraoperative blood salvage (1)
- Intrinsic resistance (1)
- Intubation (1)
- Isoflurane (1)
- Isothermal amplification (1)
- Ixodes ricinus (1)
- JAK2V617F (1)
- KCCQ (1)
- KCNQ1 (1)
- KLHL11 (1)
- KPS (1)
- Kallikrein inhibitor (1)
- Kappa (1)
- Keap1-Nrf2 (1)
- Ki-67 (1)
- Kindes- und Jugendalter (1)
- Knee surgery (1)
- Kontrazeption (1)
- LARS2 (1)
- LDHB (1)
- LEOSS (1)
- LPS (1)
- LQTS (1)
- LSCC (1)
- LSEC (1)
- LanCL2 (1)
- Lasers (1)
- Lateral flow antigen testing (1)
- Lateral flow immunoassay (1)
- Learning and memory (1)
- Lee type, functional outcome (1)
- Legal medicine (1)
- Leigh syndrome (1)
- Leishmaniasis (1)
- Lemperle (1)
- Leukemia (1)
- Leukocyte depletion filter (1)
- Lipedema (1)
- Liposuction (1)
- Liver Transplantation (1)
- Liver cancer (1)
- Liver fibrosis (1)
- Local therapy (1)
- Long non-coding RNA (1)
- Long non-coding RNAs (1)
- Low grade glioma (1)
- Low-molecular-weight heparin (1)
- Low-virulent infection (1)
- Lung neoplasms (1)
- Lymphocyte subpopulations (1)
- Lymphopenia Mortality (1)
- MDD (1)
- MEIS (1)
- MEK inhibitor (1)
- MLKL (1)
- MN1 (1)
- MRI-negative epilepsy (1)
- MTOR inhibitor (1)
- MTRasym (1)
- MVPA (1)
- MYC (1)
- MYCN amplification (1)
- Macrophage polarization (1)
- Magnetic resonance imaging (1)
- Major depressive disorder (1)
- Malaria (1)
- Malignant meningioma (1)
- Manchester scar scale (1)
- Marginal integrity (1)
- Masking effect (1)
- Mastoiditis (1)
- Matching-adjusted indirect comparison (MAIC) (1)
- Materials science (1)
- Mathematical functions (1)
- Maxillofacial reconstruction (1)
- Maxillofacial trauma (1)
- Medical history (1)
- Meersseman test (1)
- Meningioma (1)
- Mental health and psychiatry (1)
- Mental health therapies (1)
- Metabolic diseases (1)
- Metabolic dysfunction (1)
- Metabolic models (1)
- Metabolic vulnerabilities (1)
- Metalloproteinases (1)
- Metastasis-directed therapy (1)
- Metastatic castration-resistant prostate cancer (1)
- Methanol (1)
- Methicillin-resistant Staphylococcus aureus (1)
- Method validation (1)
- Methylphenidate (1)
- MiSpEx-network (1)
- Micro computed tomography (1)
- MicroRNAs (1)
- Microbiology and Infectious Disease (1)
- Microgap (1)
- Microwave ablation (1)
- Minimal invasive dentistry (1)
- Mitochondrial ROS (1)
- Mitochondrial dysfunction (1)
- Mitosis (1)
- Molecular Biology (1)
- Molecular diagnostics (1)
- Molecular neuroscience (1)
- Monoclonal antibody (mAb) (1)
- Monocytes (1)
- Mosquito (1)
- Motivation (1)
- Mountain (1)
- Multianalyte detection (1)
- Multidrug-resistant organisms (1)
- Multiligament instability (1)
- Multivariate analysis (1)
- Musculoskeletal abnormalities (1)
- Musculoskeletal problems (1)
- Musculoskeletal system (1)
- Mycobacteria (1)
- Mycobacterium avium complex (1)
- Myeloid Neoplasia (1)
- Myiasis (1)
- Myocardial infarction (1)
- Myocardial remodeling (1)
- N471D strumpellin knock-in mice (1)
- N501Y (1)
- NAFLD (1)
- NASH (1)
- NET (1)
- NFkB (1)
- NK cell subsets (1)
- NK-92 (1)
- NO (1)
- NOS-I (1)
- NOS1AP (1)
- NSBB (1)
- NURF (1)
- Natural killer cells (1)
- Necroptosis (1)
- Necrotizing enterocolitis (1)
- Negligence (1)
- Nephrectomy (1)
- Neural stem cells (1)
- Neurodegeneration (1)
- Neuroepithelial (1)
- Neuroepithelial tumor (1)
- Neurofeedback (1)
- Neurofilament light chain (1)
- Neuroligins (1)
- Neurooncology (1)
- Neuropilin (1)
- Neurotoxicity (1)
- Neurovascular damage (1)
- Next-generation sequencing (1)
- NfL (1)
- Niche (1)
- Nicotine (1)
- Nitric oxide (1)
- Nonaerosolizing treatment (1)
- Nontuberculous mycobacteria (1)
- Noradrenergic (1)
- Norepinephrine (1)
- Nox4 (1)
- Nrf-2 (1)
- Nrf2 (1)
- Nutrition (1)
- OA (1)
- OGR1 (1)
- OHIP-G14 (1)
- OHRQoL (1)
- ORP (1)
- OSCE (1)
- OXA-48 (1)
- OXA-484 (1)
- OXPHOS (1)
- Obstetrics and gynecology (1)
- Occlusion treatment (1)
- Occupational health (1)
- Older patient (1)
- Olfactory groove meningioma (1)
- Olfactory system (1)
- Oligodendroglioma (1)
- Oligometastatic (1)
- Omega lipids (1)
- Oncogenes (1)
- Oncology (1)
- Online Survey (1)
- Opinion (1)
- Opioids (1)
- Opportunistic infections (1)
- Oral food challenge (1)
- Oral immunotherapy (OIT) (1)
- Oral therapy (1)
- Orbital fracture (1)
- Organ failure (1)
- Organ injury (1)
- Orthodontic tooth movement (1)
- Osteoporotic fractures (1)
- Otorhinolaryngological (1)
- Outcomes (1)
- Outcomes research (1)
- Outpatients (1)
- Overweight (1)
- Oxidative phosphorylation (1)
- P2X7 receptor (1)
- PAC-1 (1)
- PAD-test (1)
- PAPR (1)
- PATZ1 (1)
- PBSC (1)
- PBX (1)
- PD-1 (1)
- PD-L1 (1)
- PLAGL1 (1)
- PMA (1)
- PML (1)
- PMMA (1)
- POCT (1)
- POR (1)
- PPAR-γ (1)
- PRF (1)
- PRNT (1)
- PRRT (1)
- PSA (1)
- PTEN inducible kinase 1 (1)
- PTM (1)
- Pacemaker (1)
- Pain (1)
- Pain management (1)
- Palacos reaction (1)
- Pandemie (1)
- Parenteral nutrition (1)
- Parkinson's disease (1)
- Parkinson’s disease (1)
- Particulates (1)
- Pathogens (1)
- Pathology (1)
- Pathophysiology (1)
- Patient manikins (1)
- Patient perspective (1)
- Patient preference (1)
- Patterns of care (1)
- Pediatric oncology (1)
- Pediatric stem cell transplantation (1)
- Pediatric surgery (1)
- Per1−/−-mice (1)
- Peri-implant disease (1)
- Peritoneal macrophages (1)
- Peritumoural oedema (1)
- Peri‑implantitis (1)
- Persistence SARS-CoV-2 antibodies (1)
- Personal protective equipment (1)
- Personalisierte translationale Therapie (1)
- Personalized medicine (1)
- Phagocytosis (1)
- Phantoms (imaging) (1)
- Pharmacokinetics (1)
- Pharmacology (1)
- Pharmacotherapy (1)
- Phase 3 (1)
- Phase 3 trial (1)
- Phenylketonuria (PKU) (1)
- Physical self-perception (1)
- Play (1)
- Pleasure (1)
- Pneumocystis jirovecii (1)
- Pneumonia (1)
- Podospora anserina (1)
- Point of care (1)
- Point-of-care wound diagnostics (1)
- Poly-Pore (1)
- Polypharmacy (1)
- Population dynamics (1)
- Portal veins (1)
- Post mortem examination (1)
- Post-cesarean (1)
- Post-offence drinking (1)
- Post-thaw recovery (1)
- Post-traumatic stress disorder (1)
- Postmortem (1)
- Postmortem interval (1)
- Posture analysis (1)
- Potassium iodide (1)
- Powered air-purifying respirator (1)
- Pre-analytics (1)
- Preclinical research (1)
- Prediction of locoregional recurrence (1)
- Predictive coding (1)
- Predictive markers (1)
- Predictive model (1)
- Prevention (1)
- Preventive medicine (1)
- Primary care (1)
- Primary health care (1)
- Primary molars (1)
- Primärversorgung (1)
- Principal component analysis (1)
- Prisoners (1)
- Prisons (1)
- Probability density (1)
- Probability distribution (1)
- Proficiency testing (1)
- Prognostic markers (1)
- Prognostic models (1)
- Protease inhibitor therapy (1)
- Proximal (1)
- Pseudomonas aeruginosa (1)
- Pseudophakia (1)
- Psoriasis (1)
- Psoriatic arthritis (1)
- Psychiatric disorders (1)
- Psychiatry (1)
- Psychology (1)
- Pyogenic spondylodiscitis (1)
- Python (1)
- Qualitative study (1)
- Quality control (1)
- RARP (1)
- RAS pathway (1)
- RCT (1)
- RET (1)
- RGAG1 (1)
- RMS (1)
- RNA (1)
- RNA sequencing (1)
- RNA therapeutics (1)
- RNA therapy (1)
- RNA-binding protein (1)
- RNA-sequencing (1)
- RNAP II (1)
- RND (1)
- RNF4 (1)
- ROC analyses (1)
- ROC-Analysen (1)
- ROS1 (1)
- RT-PCR-detection (1)
- Race (1)
- Radiation Oncology (1)
- Radiation necrosis (1)
- Radical prostatectomy (1)
- Radiochemotherapy (1)
- Radioiodine therapy (1)
- Radioiodine uptake test (1)
- Radiology (1)
- Radiomics (1)
- Radiosurgery (1)
- Ramucirumab (1)
- Randomisation (1)
- Randomized Controlled Trial (1)
- Randomized controlled trial (1)
- Reactive oxygen species (1)
- Ready-made mouthguard (1)
- Real-time MRI (1)
- Real-time polymerase chain reaction (PCR) tests (1)
- Rectal cancer (1)
- Redoxin (1)
- Refractive changes (1)
- Region (1)
- Registry (1)
- Renal cell carcinoma (1)
- Rescue medication (1)
- Resection (1)
- Residual myometrial thickness (1)
- Respiratory distress syndrome (1)
- Respiratory infections (1)
- Response control (1)
- Restenosis (1)
- Resting-state (1)
- Retrospective study (1)
- Reward (1)
- Rhabdomyoma (1)
- Rho-kinase (1)
- Ridge preservation (1)
- Riftia pachyptila (1)
- Risk factor (1)
- Risk stratification (1)
- Roussel Uclaf Causality Assess- ment Method (RUCAM) (1)
- S1P lyase (1)
- S63845 (1)
- SAH (1)
- SAMHD1 (1)
- SARS CoV 2 (1)
- SARS-CoV-2 testing (1)
- SARS-CoV‑2 (1)
- SCCHN (1)
- SCD14 (1)
- SEC-ICP-DRC-MS (1)
- SEER (1)
- SELEX (1)
- SF-36 (1)
- SGPL1 (1)
- SGPL1 knockout cell line (1)
- SH-SY5Y neuroblastoma cells (1)
- SIRPalpha (1)
- SIRT1 (1)
- SKALE score (1)
- SLC6a3 (1)
- SLC7A11 (1)
- SPG8 (1)
- SUMO (1)
- Safety (1)
- Salivary gland cancer (1)
- Salivary gland carcinoma (1)
- Sandfly (1)
- Sapacitabine (1)
- Sarcoma (1)
- Satisfaction (1)
- Scheimpflug imaging (1)
- Schizophrenia (1)
- Sclerotic glomeruli (1)
- Screeningfragebogen (1)
- Seasonal variation (1)
- Sedation (1)
- Sedatives (1)
- Seizures (1)
- Self-esteem (1)
- Sequencing (1)
- Short bowel syndrome (1)
- Side effect (1)
- Silver diamine fluoride (1)
- Simulated patients (1)
- Simulation training (1)
- Single-cell RNA sequencing (1)
- Skeletal health (1)
- Skull base (1)
- Slow Cortical Potentials, SCP (1)
- Smac mimetics (1)
- Smoking habits (1)
- Social Phobia (1)
- Social cognition (1)
- Social decision-making (1)
- Social neuroscience (1)
- Sociodemographic characteristics (1)
- Socket healing (1)
- Socket preservation (1)
- Soft tissue healing (1)
- Software (1)
- Solar insolation (1)
- Sonication (1)
- Sonography (1)
- Spinal fractures (1)
- Spinal surgery (1)
- Sport (1)
- Stability (1)
- Standard value (1)
- Standardization (1)
- Static MRI (1)
- Stem cell dose (1)
- Stem cell enumeration (1)
- Stereotactic ablative body radiotherapy (1)
- Stimulant (1)
- Sting challenge (1)
- Structured written feedback (1)
- Subependymal giant cell astrocytoma (1)
- Sudden Cardiac Death (SCD) (1)
- Suicidality (1)
- Sunlight (1)
- Superficial vein thrombosis (1)
- Supratentorial (1)
- Surgical blood loss (1)
- Surgical site infection (1)
- Sustained attention (1)
- Symmetrical blocked occlusion (1)
- Synaptic organizer (1)
- Synaptic transmission (1)
- Synaptosomal preparation (1)
- Syndecan-1 (1)
- Synthetic biology (1)
- Syrian hamster (1)
- Systematic review (1)
- T-cell development (1)
- T-cell receptor (TCR) (1)
- T-cells (1)
- TACE (1)
- TAM (1)
- TAVI (1)
- TDAG8 (1)
- TGF-β1 (1)
- TGFB-induced factor homeobox 1 (1)
- TGIF (1)
- TIPS (1)
- TLR4 (1)
- TME (1)
- TMT (1)
- TRAIL (1)
- TRP2 (1)
- TRPM8 (1)
- TRPV4 (1)
- TSP-4 (1)
- TTFields (1)
- TURP (1)
- TWNK (1)
- Taekwondoka (1)
- Tailored therapy (1)
- Tar (1)
- Targeted therapy (1)
- Telemedicine (1)
- Temozolomide (1)
- Tempo-parietal junction (1)
- Temporomandibular joint (1)
- Temporomandibular joint dysfunction (1)
- Tetanus (1)
- Tetrahydrobiopterin (1)
- Theft (1)
- Therapeutic anticoagulation (1)
- Thermogenesis (1)
- Thorax (1)
- Thyroid (1)
- Time of death (1)
- Time trend (1)
- Tobacco (1)
- Tomography (1)
- Tooth segmentation (1)
- Traditional Chinese Medicine (TCM) (1)
- Traditional Indian Medicine (1)
- Trajectories (1)
- Transcranial direct current stimulation (1)
- Transcription (1)
- Transcriptomics (1)
- Transdifferentiation (1)
- Transfusion (1)
- Translation (1)
- Translational research (1)
- Transplant logistics (1)
- Transplantation Centers (1)
- Travel times (1)
- Trisomy 21 (1)
- Troponin (1)
- Tuberous sclerosis complex (1)
- Tumor cell (1)
- Type three hypersensitivity (1)
- Tyrosine kinase inhibitor (TKI) (1)
- Tyrosinemia (1)
- Ulixertinib (1)
- Understanding (1)
- Undiagnosed patients (1)
- Upper airway infection (1)
- Upper body posture (1)
- Urethral cancer (1)
- Uterus (1)
- VEGF receptor 2 internalization and signaling (1)
- VEGF receptors (1)
- VRE (1)
- Vaccine (1)
- Vagus nerve (1)
- Vagus nerve stimulation (1)
- Vascular endothelial growth factor (VEGF) (1)
- Ventilators (1)
- Video rasterstereography (1)
- Virtual noncalcium reconstructions (1)
- Virus trapping (1)
- Visual quality (1)
- WASH complex subunit 5 (1)
- WIPI2 (1)
- WIPI2b (1)
- Weight distribution (1)
- White blood cells (1)
- White matter hyperintensity (1)
- Wilson disease (WD) (1)
- Wnt (1)
- Working memory capacity (1)
- Wound healing (1)
- Wounds and injuries (1)
- X-ray computed (1)
- Yoga (1)
- Zika Virus (1)
- Zika fever (1)
- Zymosan-induced peritonitis (1)
- ablation (1)
- abscisic acid (1)
- abscopal effect (1)
- acetaminophen (1)
- acne inversa (1)
- acoustic radiation force impulse (1)
- action (1)
- activated factor XIII (1)
- acute decompensation (1)
- acute pain (1)
- acute stroke care (1)
- adaptation (1)
- adenosine (1)
- adhesion (1)
- adipocytes (1)
- adipose-derived stromal/stem cells (1)
- adolescence (1)
- adolescent (1)
- adult (1)
- advanced melanoma (1)
- adversity (1)
- age (1)
- aged (1)
- agent-based models (1)
- agility (1)
- agreeableness (1)
- air abrasive (1)
- allogeneic hematological stem cell transplantation (1)
- allogeneic stem cell transplant (1)
- allostasis (1)
- alpha power (1)
- alpha-synuclein (1)
- alpha7 nicotinic acetylcholine receptor (1)
- amide proton transfer (1)
- amyotrophic lateral sclerosis (1)
- aneurysm (1)
- animal model (1)
- anorectal malformation (1)
- anti-neural autoantibodies (1)
- antiadhesive composites (1)
- antibacterial composites (1)
- antibiotic prophylactic therapy (1)
- antibiotic prophylaxis (1)
- antibiotics (1)
- anticipation (1)
- anticoagulation (1)
- antiepileptic drug (1)
- antihelix shaping (1)
- antimicrobial stewardship (1)
- antiviral signaling (1)
- anxiety (1)
- anxiety disorders (1)
- aortic root replacement (1)
- aortic valve repair (1)
- aortic valve stenosis (1)
- aortic valve-sparing (1)
- aphrodisin (1)
- apical constriction (1)
- apical polarity (1)
- aptamer (1)
- aptamer modeling (1)
- arterial stiffness (1)
- articular cartilage (1)
- artifacts (1)
- artificial feeding (1)
- artificial intelligence (1)
- artificial intelligence (AI) (1)
- assembly (1)
- assembly factor (1)
- asthma (1)
- asymptomatic temporal encephaloceles (1)
- at-risk mental state (1)
- ataxia (1)
- atopic dermatitis (1)
- atrial fibrillation (1)
- attachment (1)
- attention (1)
- attention-deficit/hyperactivity disorder (ADHD) (1)
- auditory (1)
- auditory cortex (1)
- augmentation (1)
- autism (1)
- autoantibodies (1)
- autobiographical memories (1)
- autogenous tooth roots (1)
- autoimmune encephalitis (1)
- autoimmune-mediated psychosis (1)
- automatic scene classification (1)
- autophagy inhibition (1)
- azacitidine (1)
- bacteremia (1)
- bacteria (1)
- bacterial leakage (1)
- bacterial viability (1)
- bacteriophages (1)
- ball (1)
- basilar artery occlusion (BAO) (1)
- bats (1)
- behavioral inhibition (1)
- behavioural rhythms (1)
- benfooxythiamine (1)
- best medical treatment (1)
- beta-band activity (1)
- beta-lactamases (1)
- bibliometric analysis (1)
- bilateral (1)
- bile (1)
- bile acids (1)
- binocular vision (1)
- biochemical relapse free survival (1)
- biologization (1)
- bladder neck stenosis (1)
- blood cell mutations (1)
- blood coagulation (1)
- blood concentrates (1)
- blood culture (1)
- blood transfusion (1)
- blood-brain barrier (1)
- bloodstream infections (1)
- body plethysmography (1)
- bone (1)
- bone augmentation (1)
- bone barrow (1)
- bone regeneration (1)
- bone-regeneration (1)
- bowel dysfunction (1)
- brachytherapy (1)
- brain disorders (1)
- brain imaging (1)
- brain infection (1)
- brain metastases (1)
- cAMP (1)
- cGMP (1)
- calretinin (1)
- cancer cell metabolism (1)
- cancer immunotherapy (1)
- cancer metastases (1)
- cancer specific survival (1)
- cancer surveillance (1)
- cancer therapy (1)
- cancer treatment (1)
- cancer-associated fibroblasts (1)
- cancer-specific survival (1)
- cannabinoid receptors (1)
- carbapenem resistance (1)
- carbapenemases (1)
- cardiac differentiation (1)
- cardiac magnetic resonance (1)
- cardiac regeneration (1)
- cardiac reprogramming (1)
- cardiocerebral resuscitation (1)
- cardiomyocyte apoptosis (1)
- cardiomyocyte proliferation (1)
- cardiomyocytes (1)
- cardiopulmonary resuscitation (1)
- cardiovascular disease (1)
- caregivers (1)
- cartilage (1)
- castration resistance (1)
- cell barrier integrity (1)
- cell culture (1)
- cell differentiation (1)
- cell heterogeneity (1)
- cell lines (1)
- cell proliferation regulating inhibitor of protein phosphatase 2A (1)
- cellular therapies (1)
- central nervous system (1)
- central spasticity (1)
- ceramides (1)
- cerebral imaging (1)
- cerebral ischemia (1)
- cerebral metastasis (1)
- cerebral palsy (1)
- cerebral sinus and vein thrombosis (CVT) (1)
- cervical cancer (1)
- cetuximab (1)
- chaperone-mediated autophagy (1)
- chemokines (1)
- chemoradiotherapy (1)
- childhood cancer (1)
- children and adolescents (1)
- cholesterol (1)
- cholinergic system (1)
- chronic (1)
- chronic granulomatous disease (1)
- chronic hepatitis C (1)
- chronic inflammation (1)
- classical Hodgkin lymphoma (1)
- classification (1)
- clindamycin (1)
- clinical decision-making (1)
- clinical high at-risk mental state (1)
- clinical isolates (1)
- clinical research (1)
- clinical stage (1)
- clinical teaching (1)
- clinically important restrictions and symptoms (1)
- clonal haematopoiesis (1)
- cluster analysis (1)
- cluttering (1)
- co-infection (1)
- cochlear implant (1)
- cochlear implants (1)
- collagen (1)
- collagen membranes (1)
- collective cell migration (1)
- colorectal cancer (1)
- combined modality therapy (1)
- comorbidities (1)
- complementary medicine (1)
- complete response (1)
- complex systems (1)
- compound screen (1)
- computational knowledge-discovery (1)
- computer-assisted (1)
- concordance (1)
- confinement (1)
- congenital diaphragmatic hernia (1)
- congenital disorders of autophagy (1)
- conical coupling (1)
- conometric connection (1)
- consensus (1)
- conservative dentistry (1)
- constipation (1)
- contraception (1)
- control of menstrual bleeding (1)
- convulsive seizures (1)
- coping (1)
- core expression (1)
- corona virus (1)
- coronally advanced flap (1)
- corticosteroids (1)
- cost-effective (1)
- criteria (1)
- critical-size defect (1)
- critically ill patients (1)
- cross-linking (1)
- curcumin (1)
- cyclic nucleotide analogues (1)
- cyclic nucleotide binding proteins (1)
- cycling (1)
- cyclooxygenase-2 (1)
- cytochrome P450 enzymes (1)
- cytochrome P450 reductase (1)
- cytokines (1)
- cytotoxic T lymphocyte (1)
- dance teacher (1)
- data quality (1)
- data repositories (1)
- data sharing (1)
- death rates (1)
- decompressive craniectomy (1)
- default mode network (1)
- degradation (1)
- delayed diagnosis (1)
- delivery mode (1)
- delta (1)
- dendrite morphogenesis (1)
- dendritic cells (1)
- dengue vector (1)
- dental assistant (1)
- dental education (1)
- dental implant (1)
- dental school (1)
- dental treatment concept (1)
- dentist (1)
- dentist’s chair design (1)
- depth perception (1)
- desensitization (1)
- development (1)
- diabetes complication (1)
- diabetic nephropathy (1)
- diagnosis (1)
- diet (1)
- diffuse marrow involvement (1)
- digital medicine (1)
- digital one-piece casting (1)
- digital pressing technology (1)
- digital workflow (1)
- dihydrocannabidiol (1)
- diphtheria toxin (1)
- direct-acting antiviral (DAA) treatment (1)
- discontinuation (1)
- disease progression (1)
- dislocation (1)
- disordered iron metabolism (1)
- dobutamine stress (1)
- docetaxel (DX) resistance (1)
- dopamine transporter (1)
- dorsal attention network (1)
- double immune checkpoint inhibition (1)
- downgrading (1)
- doxycycline (1)
- drinking (1)
- drospirenone (1)
- drug (1)
- drug–drug interactions (1)
- drug–gene interactions (1)
- drug–g–gene interactions (1)
- dual-energy (1)
- dynamic causal modeling (1)
- dynamic system (1)
- early onset (1)
- early-onset prostate cancer (1)
- echo planar imaging (1)
- edentulous (1)
- efferocytosis (1)
- efflux pump (1)
- egg sampling (1)
- elastin (1)
- electrical coupling (1)
- electroanatomical mapping (1)
- electrode design (1)
- electroencephalography (1)
- electroencephalography (EEG) (1)
- electrolytic cleaning (1)
- electron transfer (1)
- element speciation (1)
- emergency care (1)
- emicizumab (1)
- endodontic curriculum (1)
- endodontic education (1)
- endodontics (1)
- endothelial dysfunction (1)
- endourology (1)
- endovascular treatment (1)
- enterobacter infections; pseudomonas aeruginosa; epidemiology (1)
- enzyme activity assay (1)
- epidermal growth factor receptor (1)
- epilepsy surgery (1)
- erastin (1)
- erythropoiesis (1)
- essential thrombocythemia (ET) (1)
- ethanol (1)
- everolimus (1)
- executive functions (1)
- exercise (1)
- expert witness statement (1)
- extraskeletal (1)
- eye movements (1)
- fMLP (1)
- factor XIII (1)
- faecal microbiota transfer (1)
- fall (1)
- famotidine (1)
- fasting insulin (1)
- fat grafting (1)
- fatty acid synthesis (1)
- fecal incontinence (1)
- fecal microbiota transfer (1)
- females (1)
- fenfluramine (1)
- ferric carboxymaltose (1)
- ferric derisomaltose (1)
- ferroportin (1)
- ferroptosis (1)
- ferumoxytol (1)
- fibrinolysis (1)
- fibrosis (1)
- first-time shoulder dislocation (1)
- flow cytometry (1)
- fondaparinux (1)
- fracture strength (1)
- fracture strength equation (1)
- frontotemporal dementia (1)
- full-arch restoration (1)
- function (1)
- functional connectome acute (1)
- functional magnetic resonance imaging (1)
- functional outcome (1)
- fungal sugar (1)
- fusion (1)
- fusion kinase (1)
- gait symmetry (1)
- gargle lavage (1)
- gastrointestinal stromal tumours (1)
- gender (1)
- genetic diversity (1)
- genetic variants (1)
- genetically caused iron imbalance (1)
- genotype G (1)
- geriatrics (1)
- gingival recession therapy (1)
- glioma (1)
- glioma microenvironment (1)
- global health (1)
- glucose-6-phosphate dehydrogenase (1)
- glucosylceramides (1)
- glycoproteins (1)
- gp100 (1)
- graft-vs-host disease (1)
- granule polarization (1)
- graphic 3D models (1)
- great height (1)
- grisel syndrome (1)
- growth (1)
- growth inhibition (1)
- guided bone regeneration (1)
- guideline (1)
- haNK (1)
- haemophilia (1)
- harmonization (1)
- hatching (1)
- head and neck neoplasms (1)
- health database (1)
- health information interoperability (1)
- health-relatedquality of life (1)
- healthy control (1)
- hematotoxicity (1)
- hemorrhage (1)
- hepatitis C virus (1)
- herb-induced liver injury (HILI) (1)
- heterogeneity (1)
- high risk (1)
- high-altitude adaptation (1)
- high-altitude pulmonary hypertension (1)
- high-fat-diet (1)
- high-risk (1)
- high-risk neuroblastoma (1)
- hip osteoarthritis (hip OA) (1)
- hippocampus (1)
- histamine (1)
- histopathological growth pattern (1)
- homeodomain protein (1)
- homeostasis (1)
- hospital admission (1)
- host-microbe interaction (1)
- human allogeneic hematopoietic cell transplantation (1)
- human behaviour (1)
- human factors (1)
- human intestinal microbiota (1)
- human olfaction (1)
- human subjects (1)
- humans (1)
- hybrid materials (1)
- hybrid production (1)
- hydrogen peroxide (1)
- hypersensitivity (1)
- hypobaric hypoxia (1)
- hypophosphatemia (1)
- hypoxia inducible factor 1 alpha (1)
- iCBT (1)
- idiosyncratic drug-induced liver injury (DILI) (1)
- image-guided tissue acquisition (1)
- imaging genetics (1)
- imaging protocol (1)
- immobilization in external rotation and abduction (1)
- immune checkpoint blockade (1)
- immune checkpoint inhibitor (ICI) (1)
- immune escape (1)
- immune host defense (1)
- immune infiltration (1)
- immunohistochemistry (1)
- immunological risk (1)
- impulsivity (1)
- incidence (1)
- incontinence (1)
- induction chemotherapy (1)
- induction regimen (1)
- induction therapy (1)
- inertial motion units (1)
- infection (1)
- infection control (1)
- infection precaution (1)
- infections (1)
- infectivity (1)
- inflammasome (1)
- inflammatory bowel disease (1)
- inflammatory reaction (1)
- informal care (1)
- inherited (1)
- inhibitor (1)
- inhibitory control (1)
- injury pattern (1)
- injury prevention (1)
- inosine (1)
- insurance data (1)
- integrate-and-fire (1)
- integrative medicine (1)
- integrative neuromotor training (1)
- intellectual disability (1)
- intensive care admission and mortality (1)
- interim positron emissiontomography (1)
- interleukin-22 (1)
- international transport (1)
- interstitial multicatheter brachytherapy (1)
- intestinal iron loss (1)
- intestinal manipulation (1)
- intracellular (1)
- intracerebral hemorrhage (ICH) (1)
- intracranial hemorrhage (1)
- intranasal administration (1)
- intraoperatively molded (1)
- intravenous iron (1)
- intravenous iron therapy (1)
- intrinsic and innate immune response (1)
- invasive fungal disease (1)
- inverse spacer (1)
- inverse stage migration (1)
- iron deficiency anemia (1)
- iron isomaltoside (1)
- iron-trafficking (1)
- irritable bowel syndrome (1)
- jejunoileal atresia (1)
- joint innervation (1)
- joint load (1)
- juvenile myelomonocytic leukemia (1)
- kidney transplantation (1)
- kinematic analysis (1)
- landrace pigs (1)
- language impairment (1)
- lasso regression (1)
- layer-specificity (1)
- learning and memory (1)
- left atrial appendage occlusion (1)
- legislation (1)
- leisure-time activity (1)
- lenalidomide (1)
- leptin receptor-deficient mouse (1)
- leucocytes (1)
- leukemia (1)
- leukocytes (1)
- leukodystrophy (1)
- life table (1)
- life-expectancy (1)
- lifestyle intervention (1)
- light irradiation (1)
- limitations (1)
- lipids (1)
- lipofilling (1)
- lipofuscin (1)
- live-cell imaging (1)
- live/dead staining (1)
- liver X receptor (1)
- liver damage (1)
- liver metastasis (1)
- liver steatosis (1)
- liver stiffness (1)
- liver volume (1)
- local drug delivery (1)
- local preemptive analgesia (1)
- local recurrence (1)
- local treatment (1)
- location (1)
- locator (1)
- logistic models (1)
- long non-coding RNA (1)
- long term (1)
- long-term outcome (1)
- long-term success (1)
- loss of B-cell phenotype (1)
- loss-of-function (1)
- low molecular weight heparin (1)
- low risk (1)
- low-back-pain (1)
- low-carbohydrate (1)
- low-dose irradiation (1)
- low-glycaemic meal replacement (1)
- lower leg fracture (1)
- lung development (1)
- lung function (1)
- lungs (1)
- lymph node metastases (1)
- mRNA stability (1)
- mRNA1273 (1)
- mTOR (1)
- mTOR inhibitor (1)
- machine-learning (1)
- magnetoencephalography (1)
- male (1)
- malignancy (1)
- mammary carcinoma (1)
- manganese (1)
- marginal fit (1)
- marked lymph node (1)
- mass spectrometry (1)
- mathematical analysis (1)
- mathematical modeling (1)
- mechanotransduction (1)
- medical risk factors (1)
- medulloblastoma (1)
- melanoma (1)
- membrane-less organelles (1)
- membranous urethral stricture (1)
- meningioma (1)
- mental health (1)
- mesenchymal stromal cell (1)
- mesenchymal stromal/stem cells (1)
- mesial temporal lobe epilepsy (1)
- meta-analysis (1)
- metabolic liver disease (1)
- metabolic rewiring (1)
- metabolism (1)
- metabolomics (1)
- metastatic renal cell carcinoma (1)
- mice (1)
- michael acceptor (1)
- microbiome (1)
- microdissection (1)
- microsurgery (1)
- microvesicles (1)
- mild cognitive impairment (1)
- minimally invasive therapy (1)
- minocycline (1)
- mitochondrial disease (1)
- mitochondrial respiration (1)
- mitral regurgitation (1)
- mitral valve surgery (1)
- mold (1)
- molecular marker (1)
- molecular neuroscience (1)
- molecular surveillance (1)
- monitoring (1)
- monoacylglycerol lipase (1)
- monoclonal antibodies (1)
- monoclonal antibody (1)
- monocytes (1)
- monotherapy (1)
- mood (1)
- morbidity (1)
- motor functions (1)
- motor-control-exercise (1)
- mouse (1)
- mouse models (1)
- mouse tumor model (1)
- mucormycetes (1)
- multi-material 3D printing (1)
- multi-scale models (1)
- multicenter study (1)
- multicentre study (1)
- multidisciplinary-therapy (1)
- multimorbidity (1)
- multiple myeloma (1)
- multisensory integration (1)
- multislice imaging (1)
- multivoxel pattern analysis (1)
- musculoskeletal disorders (1)
- musculoskeletal repair (1)
- musculoskeletal system (1)
- mutation (1)
- mutism (1)
- myeloproliferative neoplasms (MPN) (1)
- myocardial efficiency (1)
- myocardial fibrosis (1)
- myocardial ischaemia (1)
- myocardial power (1)
- nNOS (1)
- nasal swab (1)
- natural selection (1)
- natural sounds (1)
- necroptosis (1)
- neoadjuvant therapy (1)
- neonate (1)
- neovascularization (1)
- neural correlates (1)
- neural oscillations (1)
- neurodegeneration (1)
- neurodevelopment (1)
- neurodevelopmental disorde (1)
- neuroendocrine tumor (1)
- neuroethology (1)
- neurogenic bowel (1)
- neuroimaging (1)
- neurological manifestations (1)
- neurology (1)
- neuropeptide (1)
- neuropeptides (1)
- neuroprotection (1)
- neurotransmitter (1)
- neutralization (1)
- neutralizing antibody (1)
- next-generation sequencing (1)
- nitric oxide (1)
- nitroalkene (1)
- nitroglycerin (1)
- nociception (1)
- nodular lymphocyte-predominant Hodgkin lymphoma (1)
- nomogram (1)
- non-aneurysmal (1)
- non-aneurysmal SAH (1)
- non-coding RNA (1)
- non-contact injuries (1)
- non-perimesencephalic (1)
- non-small cell lung cancer (1)
- nontraumatic atlantoaxial rotatory subluxation (1)
- nucleic acid amplification test (1)
- nucleic acid docking (1)
- nucleic acid lateral flow immunoassay (1)
- nucleolus (1)
- nucleoredoxin (1)
- nutrition - clinical (1)
- nymphs (1)
- obesity (1)
- observational study (1)
- olfaction (1)
- oluble epoxide hydrolase (1)
- oncogenesis (1)
- oncogenic RAS (1)
- oncological exercise therapy (1)
- online intervention (1)
- online research (1)
- online survey (1)
- open field behavior (1)
- open science (1)
- open skill exercise (1)
- operating microscope (1)
- oral health (1)
- oral health burden (1)
- oral progestins (1)
- orale Gestagene (1)
- ordinary differential equations (ODE) (1)
- organ preservation (1)
- organic nitrates (1)
- organotypic culture (1)
- other cause mortality (1)
- otoplasty (1)
- outcomes (1)
- ovarian cancer (1)
- overdenture (1)
- overtreatment (1)
- overweight (1)
- oviposition (1)
- oviposition substrate (1)
- ovitrap (1)
- oxaliplatin (1)
- oxythiamine (1)
- p-eIF2α (1)
- p21Cip1/CDKN1A (1)
- p53 pathway (1)
- pH (1)
- pad-test (1)
- pain intensity (1)
- paired samples (1)
- palliative care (1)
- palliative care services (1)
- pancreatic ductal adenocarcinoma (1)
- pannexin-1 (1)
- paper-based detection (1)
- paracrine signaling (1)
- parent rating (1)
- pathogen (1)
- patient preferences (1)
- patient safety (1)
- patient–doctor relationship (1)
- pediatric solid tumors (1)
- pelvic trauma (1)
- penile cancer (1)
- pentaerythritol tetranitrate (1)
- peptide receptor radionuclide therapy (1)
- perforant path transection (1)
- peri-implant disease (1)
- peri-implant diseases (1)
- peri-implantitis (1)
- peri-implantitis treatment (1)
- periimplantitis (1)
- perimesencephalic (1)
- periodontal diseases (1)
- periodontal treatment (1)
- peripheral blood stem cell collection (1)
- peritoneal macrophages (1)
- peritumoral edema (1)
- peritumoral edema zone (1)
- peroxisome proliferator-activated receptor (1)
- persistent periodontal pockets (1)
- personalized (1)
- phagocytes (1)
- phagocytosis (1)
- pharmacodynamics (1)
- pharmacoepigenetics (1)
- pharmacogenetics (1)
- pharmacological data science (1)
- pharmacological plasticity (1)
- phase IV (1)
- phase separation (1)
- phenoconversion (1)
- pheromone (1)
- phosphoproteomics (1)
- photodynamic therapy (1)
- physical activity (1)
- physiotherapy (1)
- pitch (1)
- plasmid (1)
- platelet hyperactivity (1)
- platelet substitution (1)
- platelet-rich-fibrin (1)
- point-of-care diagnostics (1)
- polo-like kinases (1)
- polyQ (1)
- polycythemia vera (PV) (1)
- polymer infiltrated ceramic network (1)
- polymeric micelle (1)
- polypept(o)ide (1)
- polypharmacy (1)
- polytrauma (1)
- polyunsaturated fatty acid (1)
- portal pressure (1)
- positron-emissions-tomography (1)
- post-transcriptional regulation (1)
- posterior circulation (1)
- postinfectious bronchiolitis obliterans (1)
- postoperative pain (1)
- potassium channel (1)
- preclinical (1)
- prediabetes and type 2 diabetes (1)
- prediction (1)
- predictive (1)
- predictive coding (1)
- predictor (1)
- preeclampsia (1)
- prehabilitation (1)
- prepontine (1)
- preventive strategies (1)
- primary biliary cholangitis (1)
- primary immunodeficiency (1)
- primary myelofibrosis (PMF) (1)
- prion-like (1)
- production (1)
- progestin mono-preparation (1)
- prognostic (1)
- prognostic scores (1)
- progranulin (1)
- promyelocytic leukemia nuclear bodies (1)
- prostate cancer (PCa) (1)
- prostate neoplasm (1)
- proteasome (1)
- protein aggregation (1)
- protein complexes (1)
- protein evolution (1)
- protein folding (1)
- protein phosphorylation (1)
- protein-rich (1)
- protein–protein interaction (1)
- proteoglycan (1)
- proteomics (1)
- proton pumping (1)
- proton-sensing GPCR (1)
- protruding ear (1)
- pseudomonas aeruginosa (1)
- psoriasis (1)
- psychiatric disorders (1)
- psychogenic non-epileptic seizures (1)
- psychosocial factors (1)
- public health (1)
- publication output (1)
- pulsed SILAC (1)
- quantitative MRI (1)
- quantitative RUCAM (1)
- quantitative magnetic resonance imaging (1)
- quiescence (1)
- radiation (1)
- radiation-induced (1)
- radio sensitivity (1)
- radioimmunotherapy (1)
- radiomics (1)
- randomized (1)
- randomized controlled trial (1)
- rare disease (1)
- rare mendelian disorders (1)
- rat calvaria defect (1)
- re-irradiation (1)
- reactive coordination (1)
- reactive oxygen species (1)
- real-world (1)
- recall (1)
- recombinase polymerase amplification (1)
- recovery (1)
- recurrent urinary tract infections (1)
- red cells (1)
- reduced kidney function (1)
- reduction potential (1)
- regenerative therapy (1)
- relapsing–remitting multiple sclerosis (1)
- remodeling (1)
- renal cell carcinoma (1)
- renal dysfunction (1)
- renal failure (1)
- renal tubular epithelial cells (1)
- research database (1)
- research funding (1)
- resectability (1)
- resin nano ceramics (1)
- resistance (1)
- resistance mutation (1)
- resolution (1)
- response (1)
- response inhibition (1)
- resting-state (1)
- reticulocyte hemoglobin equivalent (1)
- retrospective studies (1)
- reverberation (1)
- revision knee arthroplasty (1)
- reward (1)
- reward probabilities (1)
- rheumatoid arthritis (1)
- rifampicin (1)
- risk group (1)
- risk stratification (1)
- room simulation (1)
- safety attitudes questionnaire (1)
- salience network (1)
- saliva (1)
- salvage mastectomy (1)
- salvage radical prostatectomy (1)
- sampling (1)
- sarcoma (1)
- scar (1)
- schizophrenia (1)
- screening questionnaire (1)
- searchlight analysis (1)
- second line therapy (1)
- second-line immunotherapy (1)
- second-line treatment / 2L treatment (1)
- secondary data analysis (1)
- secondary progressive multiple sclerosis (1)
- secreted Ly-6/uPAR-related protein 1 (1)
- seed and soil (1)
- self-collected samples (1)
- semiquinone (1)
- sensory loss (1)
- sensory organ development (1)
- serine protease (NS3-4A) (1)
- serum (1)
- severely injured patient (1)
- sex (1)
- sexual arousal (1)
- sexual dysfunction (1)
- sexual rehabilitation (1)
- shared decision-making (1)
- shear stress (1)
- shikonin (SHI) (1)
- short bowel (1)
- short linear motif (1)
- short-term (1)
- shoulder instability (1)
- shoulder stabilization (1)
- simulation (1)
- simulation training (1)
- sleep deprivation (1)
- sleep disordered breathing (1)
- small bowel (1)
- small ubiquitin-related modifier (1)
- social anxiety (1)
- social communication (1)
- socio-economic influences (1)
- socioeconomic factors (1)
- soft tissue (1)
- soft tissue sarcoma (1)
- solid tumor (1)
- sonoSens (1)
- sorafenib (1)
- sound-induced flash illusion (1)
- spared nerve injury (1)
- speech perception (1)
- sphingolipids (1)
- sphingosine-1-phosphate (1)
- spike mutation (1)
- spike protein (1)
- spina bifida (1)
- spinal bone metastasis (1)
- spinal infection (1)
- spine injury (1)
- spinocerebellar ataxia (1)
- splicing (1)
- split-mouth (1)
- sprouting (1)
- sprouting angiogenesis (1)
- stage (1)
- stage migration (1)
- statin (1)
- statin treatment (1)
- statins (1)
- stoma (1)
- structure-function (1)
- strumpellin (1)
- stuttering (1)
- subarachnoid hemorrhage (1)
- subchondral bone (1)
- subgrouping (1)
- subpopulation (1)
- sulforaphane (1)
- sulfur-oxidizing symbiont (1)
- superparamagnetic iron oxide nanoparticles (1)
- support (1)
- suprachiasmatic nucleus (1)
- surgical complications (1)
- surrogate ELISA (1)
- symbiosis (1)
- symptoms (1)
- synoviocytes (1)
- synovitis (1)
- systematic review (1)
- tDCS (1)
- tVNS (1)
- tachycardia (1)
- target (1)
- targeted axillary dissection (1)
- targeted sequencing (1)
- taste buds (1)
- temporal encephaloceles (1)
- temporal lobe epilepsy (1)
- testosterone (1)
- tetracycline (1)
- tetrahydrobiopterin (1)
- tetrahydrocannabinol (1)
- therapy (1)
- therapy response (1)
- thermal ablation (1)
- thrombectomy (1)
- thromboembolism (1)
- thymic selection (1)
- tibial fracture (1)
- tip cell filopodia formation (1)
- tissue reconstruction (1)
- toddler’s fracture (1)
- tolerability (1)
- topical administration (1)
- topographical pattern (1)
- torticollis (1)
- total hip replacement (1)
- toxic milk mice (TX mice) (1)
- toxicity (1)
- traditional Chinese medicine (TCM) (1)
- trafficking (1)
- training (1)
- transduction (1)
- transfer entropy (1)
- transglutaminase (1)
- transient elastography (1)
- transjugular intrahepatic portosystemic shunt (1)
- translational investigation (1)
- translational study (1)
- transmission (1)
- transovarial transmission (1)
- transplant-free survival (1)
- transstadial transmission (1)
- trauma (1)
- traumatic brain injury (1)
- traumatic injury (1)
- treatment outcome (1)
- treatment resistance (1)
- treatment response (1)
- trials registry (1)
- triplex (1)
- trophoblast organoids (1)
- trophoblasts (1)
- trough levels (1)
- tumor immunity (1)
- tumor immunology (1)
- tumor stroma (1)
- tumor-associated macrophages (TAM) (1)
- tunnel technique (1)
- type 2 diabetes (1)
- tyrosine hydroxylase (1)
- tyrosine kinase inhibitor (TKI) (1)
- ubiquitin ligase (1)
- ultra-high risk for psychosis (1)
- unacceptable antigen mismatches (1)
- undifferentiated pleomorphic sarcoma (1)
- unilateral (1)
- unilateral hip osteoarthritis (1)
- upgrading (1)
- urethal stricture (1)
- urethroplasty (1)
- urinary incontinence (1)
- ursodeoxycholic acid (1)
- uveal melanoma (1)
- vaccine-induced immune thrombotic thrombocytopenia (VITT) (1)
- vaginal breech (1)
- vaginal hysterectomy (1)
- variants of concern (1)
- vascular biology (1)
- vasodilation (1)
- vector (1)
- venous thrombosis (1)
- ventral otoplasty (1)
- ventral striatum (1)
- ventricular tachycardia (1)
- vergence (1)
- vertigo (1)
- very high-risk (1)
- vestibular function (1)
- viral fitness (1)
- virus (1)
- viruses (1)
- volumetric measurement technology (1)
- von Willebrand disease (1)
- waiting time (1)
- walking (1)
- wearable sensors (1)
- weight reduction (1)
- white matter hyperintensity (1)
- whole-genome sequencing (1)
- work place evaluation (1)
- wound exudate (1)
- wound healing (1)
- wound infection (1)
- wound repair (1)
- yellow flags (1)
- younger (1)
- zinc protoporphyrin (1)
- Übergewicht (1)
- ß-amyloid (1)
- β-HCG (1)
Institute
- Medizin (662)
- Biochemie, Chemie und Pharmazie (8)
- Biowissenschaften (7)
- Psychologie und Sportwissenschaften (6)
- Buchmann Institut für Molekulare Lebenswissenschaften (BMLS) (5)
- Georg-Speyer-Haus (4)
- Physik (3)
- Biodiversität und Klima Forschungszentrum (BiK-F) (2)
- Ernst Strüngmann Institut (2)
- Erziehungswissenschaften (2)
Although anti-cancer properties of the natural compound curcumin have been reported, low absorption and rapid metabolisation limit clinical use. The present study investigated whether irradiation with visible light may enhance the inhibitory effects of low-dosed curcumin on prostate cancer cell growth, proliferation, and metastasis in vitro. DU145 and PC3 cells were incubated with low-dosed curcumin (0.1–0.4 µg/mL) and subsequently irradiated with 1.65 J/cm2 visible light for 5 min. Controls remained untreated and/or non-irradiated. Cell growth, proliferation, apoptosis, adhesion, and chemotaxis were evaluated, as was cell cycle regulating protein expression (CDK, Cyclins), and integrins of the α- and β-family. Curcumin or light alone did not cause any significant effects on tumor growth, proliferation, or metastasis. However, curcumin combined with light irradiation significantly suppressed tumor growth, adhesion, and migration. Phosphorylation of CDK1 decreased and expression of the counter-receptors cyclin A and B was diminished. Integrin α and β subtypes were also reduced, compared to controls. Irradiation distinctly enhances the anti-tumor potential of curcumin in vitro and may hold promise in treating prostate cancer.
Sphingosine 1 phosphate (S1P) lyase (Sgpl1) catalyses the irreversible cleavage of S1P and thereby the last step of sphingolipid degradation. Loss of Sgpl1 in humans and mice leads to accumulation of sphingolipids and multiple organ injuries. Here, we addressed the role of hepatocyte Sgpl1 for regulation of sphingolipid homoeostasis by generating mice with hepatocyte-specific deletion of Sgpl1 (Sgpl1HepKO mice). Sgpl1HepKO mice had normal body weight, liver weight, liver structure and liver enzymes both at the age of 8 weeks and 8 months. S1P, sphingosine and ceramides, but not glucosylceramides or sphingomyelin, were elevated by ~1.5–2-fold in liver, and this phenotype did not progress with age. Several ceramides were elevated in plasma, while plasma S1P was normal. Interestingly, S1P and glucosylceramides, but not ceramides, were elevated in bile of Sgpl1HepKO mice. Furthermore, liver cholesterol was elevated, while LDL cholesterol decreased in 8-month-old mice. In agreement, the LDL receptor was upregulated, suggesting enhanced uptake of LDL cholesterol. Expression of peroxisome proliferator-activated receptor-γ, liver X receptor and fatty acid synthase was unaltered. These data show that mouse hepatocytes largely compensate the loss of Sgpl1 by secretion of accumulating sphingolipids in a specific manner into blood and bile, so that they can be excreted or degraded elsewhere.
Objective: Dravet syndrome (DS) is a rare but severe drug-resistant epilepsy. Before the approval of fenfluramine (FFA) for the treatment of seizures in DS, patients in Germany could receive treatment under a compassionate use program (CUP). Methods: We conducted a multicenter, retrospective, observational study to describe the efficacy, tolerability, and retention of FFA within the CUP. Patients received add-on therapy with oral FFA gradually titrated to a target dose between .13 and .7 mg/kg/day Results: Overall, 78 patients with DS (median age = 8.0 years, range = 2.1–46.0; 53% female, median concomitant antiseizure medications [ASMs] = 3) were treated with FFA for a median duration of 255.5 days (range = 31–572). Responder rates (a ≥50% reduction; n = 78) and seizure-freedom rates at 3 months were 68% and 14% for total seizures, respectively, and 67% and 23% for generalized tonic–clonic seizures. Responder rates were consistent at 6 and 12 months (n = 66 and n = 43, respectively). Median seizure days per month significantly decreased from 10.0 (range = .5–30) to 3.0 (range = 0–30) in the 3-month period before and after FFA treatment (p < .001). Significantly fewer patients reported at least one episode of status epilepticus (28% vs. 14% patients before and after FFA initiation, p = .005). During FFA treatment, 35 (45%) patients were able to discontinue a concomitant ASM. At the last follow-up date, 66 (85%) patients remained on treatment with FFA. The most common adverse events were somnolence (36%), decreased appetite (22%), and ataxia (8%). Forty-eight (62%) patients were reported as having a meaningful global clinical improvement. Significance: In a large cohort of patients, FFA demonstrated efficacy across a range of outcomes including clinically significant reductions in convulsive seizures, and was well tolerated, providing valuable information for real-world practice.
Background: To test the effect of urological primary cancers (bladder, kidney, testis, upper tract, penile, urethral) on overall mortality (OM) after secondary prostate cancer (PCa). Methods: Within the Surveillance, Epidemiology and End Results (SEER) database, patients with urological primary cancers and concomitant secondary PCa (diagnosed 2004-2016) were identified and were matched in 1:4 fashion with primary PCa controls. OM was compared between secondary and primary PCa patients and stratified according to primary urological cancer type, as well as to time interval between primary urological cancer versus secondary PCa diagnoses. Results: We identified 5,987 patients with primary urological and secondary PCa (bladder, n = 3,287; kidney, n = 2,127; testis, n = 391; upper tract, n = 125; penile, n = 47; urethral, n = 10) versus 531,732 primary PCa patients. Except for small proportions of Gleason grade group and age at diagnosis, PCa characteristics between secondary and primary PCa were comparable. Conversely, proportions of secondary PCa patients which received radical prostatectomy were smaller (29.0 vs. 33.5%), while no local treatment rates were higher (34.2 vs. 26.3%). After 1:4 matching, secondary PCa patients exhibited worse OM than primary PCa patients, except for primary testis cancer. Here, no OM differences were recorded. Finally, subgroup analyses showed that the survival disadvantage of secondary PCa patients decreased with longer time interval since primary cancer diagnosis. Conclusions: After detailed matching for PCa characteristics, secondary PCa patients exhibit worse survival, except for testis cancer patients. The survival disadvantage is attenuated, when secondary PCa diagnosis is made after longer time interval, since primary urological cancer diagnosis.
The capacity of convalescent and vaccine-elicited sera and monoclonal antibodies (mAb) to neutralize SARS-CoV-2 variants is currently of high relevance to assess the protection against infections. We performed a cell culture-based neutralization assay focusing on authentic SARS-CoV-2 variants B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.427/B.1.429 (Epsilon), all harboring the spike substitution L452R. We found that authentic SARS-CoV-2 variants harboring L452R had reduced susceptibility to convalescent and vaccine-elicited sera and mAbs. Compared to B.1, Kappa and Delta showed a reduced neutralization by convalescent sera by a factor of 8.00 and 5.33, respectively, which constitutes a 2-fold greater reduction when compared to Epsilon. BNT2b2 and mRNA1273 vaccine-elicited sera were less effective against Kappa, Delta, and Epsilon compared to B.1. No difference was observed between Kappa and Delta towards vaccine-elicited sera, whereas convalescent sera were 1.51-fold less effective against Delta, respectively. Both B.1.617 variants Kappa (+E484Q) and Delta (+T478K) were less susceptible to either casirivimab or imdevimab. In conclusion, in contrast to the parallel circulating Kappa variant, the neutralization efficiency of convalescent and vaccine-elicited sera against Delta was moderately reduced. Delta was resistant to imdevimab, which, however, might be circumvented by combination therapy with casirivimab together.
The scope of extracorporeal membrane oxygenation (ECMO) is expanding, nevertheless, pharmacokinetics in patients receiving cardiorespiratory support are fairly unknown leading to unpredictable drug concentrations. Currently, there are no clear guidelines for antibiotic dosing during ECMO. This study aims to evaluate the pharmacokinetics (PK) of cefazolin in patients undergoing ECMO treatment. Total and unbound plasma cefazolin concentration of critically ill patients on veno-arterial ECMO were determined. Observed PK was compared to dose recommendations calculated by an online available, free dosing software. Concentration of cefazolin varied broadly despite same dosage in all patients. The mean total and unbound plasma concentration were high showing significantly (p = 5.8913 E−09) greater unbound fraction compared to a standard patient. Cefazolin clearance was significantly (p = 0.009) higher in patients with preserved renal function compared with CRRT. Based upon the calculated clearance, the use of dosing software would have led to lower but still sufficient concentrations of cefazolin in general. Our study shows that a “one size fits all” dosing regimen leads to excessive unbound cefazolin concentration in these patients. They exhibit high PK variability and decreased cefazolin clearance on ECMO appears to compensate for ECMO- and critical illness-related increases in volume of distribution.
Peri-implantitis: summary and consensus statements of group 3. The 6th EAO Consensus Conference 2021
(2021)
Objective: To evaluate the influence of implant and prosthetic components on peri-implant tissue health. A further aim was to evaluate peri-implant soft-tissue changes following surgical peri-implantitis treatment. Materials and methods: Group discussions based on two systematic reviews (SR) and one critical review (CR) addressed (i) the influence of implant material and surface characteristics on the incidence and progression of peri-implantitis, (ii) implant and restorative design elements and the associated risk for peri-implant diseases, and (iii) peri-implant soft-tissue level changes and patient-reported outcomes following peri-implantitis treatment. Consensus statements, clinical recommendations, and implications for future research were discussed within the group and approved during plenary sessions. Results: Data from preclinical in vivo studies demonstrated significantly greater radiographic bone loss and increased area of inflammatory infiltrate at modified compared to non-modified surface implants. Limited clinical data did not show differences between modified and non-modified implant surfaces in incidence or progression of peri-implantitis (SR). There is some evidence that restricted accessibility for oral hygiene and an emergence angle of >30 combined with a convex emergence profile of the abutment/prosthesis are associated with an increased risk for peri-implantitis (CR). Reconstructive therapy for peri-implantitis resulted in significantly less soft-tissue recession, when compared with access flap. Implantoplasty or the adjunctive use of a barrier membrane had no influence on the extent of peri-implant mucosal recession following peri-implantitis treatment (SR).
Background: Treatment of acute stroke is highly time-dependent and performed by a multiprofessional, interdisciplinary team. Interface problems are expectable and issues relevant to patient safety are omnipresent. The Safety Attitudes Questionnaire (SAQ) is a validated and widely used instrument to measure patient safety climate. The objective of this study was to evaluate the SAQ for the first time in the context of acute stroke care. Methods: A survey was carried out during the STREAM trial (NCT 032282) at seven university hospitals in Germany from October 2017 to October 2018. The anonymous survey included 33 questions (5-point Likert scale, 1 = disagree to 5 = agree) and addressed the entire multiprofessional stroke team. Statistical analyses were used to examine psychometric properties as well as descriptive findings. Results: 164 questionnaires were completed yielding a response rate of 66.4%. 67.7% of respondents were physicians and 25.0% were nurses. Confirmatory Factor Analysis revealed that the original 6-factor structure fits the data adequately. The SAQ for acute stroke care showed strong internal consistency (α = 0.88). Exploratory analysis revealed differences in scores on the SAQ dimensions when comparing physicians to nurses and when comparing physicians according to their duration of professional experience. Conclusion: The SAQ is a helpful and well-applicable tool to measure patient safety in acute stroke care. In comparison to other high-risk fields in medicine, patient safety climate in acute stroke care seems to be on a similar level with the potential for further improvements. Trial registration: www.ClinicalTrials.gov Identifier: NCT032282.
Hematopoietic stem cell transplantation (HSCT) is widely used in pediatric patients as a successful curative therapy for life-threatening conditions. The treatment is intensive, with risks of serious complications and lethal outcomes. This study aimed to provide insight into current data on the place and cause of death of transplanted children, the available specialized pediatric palliative care services (SPPCS), and what services HSCT professionals feel the SPPCS team should provide. First, a retrospective database analysis on the place and cause of death of transplanted pediatric HSCT patients was performed. Second, a survey was performed addressing the availability of and views on SPPCS among HSCT professionals. Database analysis included 233 patients of whom the majority died in-hospital: 38% in the pediatric intensive care unit, 20% in HSCT units, 17% in other hospitals, and 14% at home or in a hospice (11% unknown). For the survey, 98 HSCT professionals from 54 centers participated. Nearly all professionals indicated that HSCT patients should have access to SPPCS, especially for pain management, but less than half routinely referred to this service at an early stage. We, therefore, advise HSCT teams to integrate advance care planning for pediatric HSCT patients actively, ideally from diagnosis, to ensure timely SPPCS involvement and maximize end-of-life preparation.
Platelets comprise a highly interactive immune cell subset of the circulatory system traditionally known for their unique haemostatic properties. Although platelets are considered as a vault of growth factors, cytokines and chemokines with pivotal role in vascular regeneration and angiogenesis, the exact mechanisms by which they influence vascular endothelial cells (ECs) function remain underappreciated. In the present study, we examined the role of human IL-17A/IL-17RA axis in platelet-mediated pro-angiogenic responses. We reveal that IL-17A receptor (IL-17RA) mRNA is present in platelets transcriptome and a profound increase is documented on the surface of activated platelets. By quantifying the protein levels of several factors, involved in angiogenesis, we identified that IL-17A/IL17RA axis selectively induces the release of vascular endothelial growth factor, interleukin -2 and -4, as well as monocyte chemoattractant protein -1 from treated platelets. However, IL-17A exerted no effect on the release of IL-10, an anti-inflammatory factor with potentially anti-angiogenic properties, from platelets. Treatment of human endothelial cell two-dimensional tubule networks or three-dimensional spheroid and mouse aortic ring structures with IL-17A-induced platelet releasate evoked pro-angiogenic responses of ECs. Our findings suggest that IL-17A may critically affect platelet release of pro-angiogenic factors driving ECs towards a pro-angiogenic state.
Container-breeding Aedes spp. (Diptera: Culicidae) mosquitoes can be surveilled at low cost using ovitraps. Hence, this method is a preferred monitoring approach of dengue vectors in low-resource settings. The ovitraps consist of a cup filled with water and an oviposition substrate for female mosquitoes. The attractiveness of the substrates for female mosquitoes can greatly differ due to differences in texture, color, and smell of the materials used. We compare four oviposition substrates, which are all low priced, easy to transport, and easy to purchase, to maximize the success of Aedes egg sampling. Sampled egg material is often reared to adulthood for further taxonomic identification and transported to (international) laboratories for specialized vector research. Here we introduce a transport technique for sampled eggs. In addition, we explored the impact of international transport by means of a bilateral hatching experiment in Nepal, the country of origin, and in Germany, in a laboratory specialized in ecophysiological research. The best low-cost oviposition substrate for the dengue vectors Aedes albopictus (Skuse) and Aedes aegypti (L.) was found to be a white cotton sheet. The introduced transport technique of sampled eggs is easy to build from laboratory and household materials and ensures good transport conditions (i.e., temperature and relative humidity). Even under good temperature (17.4–31.0 °C) and humidity conditions (58.9–94.2%), hatching success of eggs was found to be reduced after international transport to Germany when compared to the hatching success of eggs in Nepal. We postulate that air pressure during international transport may have reduced the hatching success and strongly recommend pressure-regulated transport boxes for egg transport via airplane. As the proposed operation procedure is useful in assisting the monitoring of Ae. albopictus and Ae. aegypti in low-resource settings, Aedes researchers are encouraged to follow it for the sampling and transport of Aedes eggs.
Background: One of the lesser recognized complications of diabetes mellitus are musculoskeletal (MSK) complications of the upper and lower extremity. No prevalence studies have been conducted in general practice. Thus, the aim of this study was to investigate the prevalence of upper extremity MSK disorders in patients with type 2 diabetes (T2DM) in the Netherlands. Methods: We conducted a cross-sectional study with two different approaches, namely a representative Dutch primary care medical database study and a questionnaire study among patients with T2DM. Results: In the database study, 2669 patients with T2DM and 2669 non-diabetes patients were included. MSK disorders were observed in 16.3% of patients with T2DM compared to 11.2% of non-diabetes patients (p < 0.001, OR 1.53, 95% CI 1.31, 1.80). In the questionnaire study, 200 patients with T2DM were included who reported a lifetime prevalence of painful upper extremity body sites for at least four weeks of 67.3%. Conclusion: We found that upper extremity MSK disorders have a high prevalence in Dutch patients with T2DM presenting in general practice. The prevalence ranges from 16% based on GP registered disorders and complaints to 67% based on self-reported diagnosis and pain. Early detection and treatment of these disorders may play a role in preventing the development of chronic MSK disorders.
Biological exploration of early biomarkers for chronic kidney disease (CKD) in (pre)diabetic individuals is crucial for personalized management of diabetes. Here, we evaluated two candidate biomarkers of incident CKD (sphingomyelin (SM) C18:1 and phosphatidylcholine diacyl (PC aa) C38:0) concerning kidney function in hyperglycemic participants of the Cooperative Health Research in the Region of Augsburg (KORA) cohort, and in two biofluids and six organs of leptin receptor-deficient (db/db) mice and wild type controls. Higher serum concentrations of SM C18:1 and PC aa C38:0 in hyperglycemic individuals were found to be associated with lower estimated glomerular filtration rate (eGFR) and higher odds of CKD. In db/db mice, both metabolites had a significantly lower concentration in urine and adipose tissue, but higher in the lungs. Additionally, db/db mice had significantly higher SM C18:1 levels in plasma and liver, and PC aa C38:0 in adrenal glands. This cross-sectional human study confirms that SM C18:1 and PC aa C38:0 associate with kidney dysfunction in pre(diabetic) individuals, and the animal study suggests a potential implication of liver, lungs, adrenal glands, and visceral fat in their systemic regulation. Our results support further validation of the two phospholipids as early biomarkers of renal disease in patients with (pre)diabetes.
Electroencephalography (EEG) represents a widely established method for assessing altered and typically developing brain function. However, systematic studies on EEG data quality, its correlates, and consequences are scarce. To address this research gap, the current study focused on the percentage of artifact-free segments after standard EEG pre-processing as a data quality index. We analyzed participant-related and methodological influences, and validity by replicating landmark EEG effects. Further, effects of data quality on spectral power analyses beyond participant-related characteristics were explored. EEG data from a multicenter ADHD-cohort (age range 6 to 45 years), and a non-ADHD school-age control group were analyzed (ntotal = 305). Resting-state data during eyes open, and eyes closed conditions, and task-related data during a cued Continuous Performance Task (CPT) were collected. After pre-processing, general linear models, and stepwise regression models were fitted to the data. We found that EEG data quality was strongly related to demographic characteristics, but not to methodological factors. We were able to replicate maturational, task, and ADHD effects reported in the EEG literature, establishing a link with EEG-landmark effects. Furthermore, we showed that poor data quality significantly increases spectral power beyond effects of maturation and symptom severity. Taken together, the current results indicate that with a careful design and systematic quality control, informative large-scale multicenter trials characterizing neurophysiological mechanisms in neurodevelopmental disorders across the lifespan are feasible. Nevertheless, results are restricted to the limitations reported. Future work will clarify predictive value.
Coagulation factor XIII (FXIII) is a protransglutaminase which plays an important role in clot stabilization and composition by cross-linking the α- and γ-chains of fibrin and increasing the resistance of the clot to mechanical and proteolytic challenges. In this study, we selected six DNA aptamers specific for activated FXIII (FXIIIa) and investigated the functional characterization of FXIIIa after aptamer binding. One of these aptamers, named FA12, efficiently captures FXIIIa even in the presence of zymogenic FXIII subunits. Furthermore, this aptamer inhibits the incorporation of FXIII and α2-antiplasmin (α2AP) into fibrin(ogen) with IC50-values of 38 nM and 17 nM, respectively. In addition to FA12, also another aptamer, FA2, demonstrated significant effects in plasma-based thromboelastometry (rotational thromboelastometry analysis, ROTEM)-analysis where spiking of the aptamers into plasma decreased clot stiffness and elasticity (p < 0.0001). The structure–function correlations determined by combining modeling/docking strategies with quantitative in vitro assays revealed spatial overlap of the FA12 binding site with the binding sites of two FXIII substrates, fibrinogen and α2AP, while FA2 binding sites only overlap those of fibrinogen. Taken together, these features especially render the aptamer FA12 as an interesting candidate molecule for the development of FXIIIa-targeting therapeutic strategies and diagnostic assays.
Simple Summary: Children with acute myeloid leukemia (AML) experience high relapse rates of about 30%; still, survival rates following the first relapse are encouraging. Hence, it is critically important to examine the consequences of a second relapse; however, little is known about this subgroup of patients. This retrospective population-based analysis intends to describe response, survival and prognostic factors relevant for the survival of children with second relapse of AML. Treatment approaches include many different therapeutic regimens, including palliation and intensive treatment with curative intent (63% of the patients). Survival is poor; however, patients who respond to reinduction attempts can be rescued with subsequent hematopoietic stem cell transplantation. We deciphered risk factors, such as short time interval from first to second relapse below one year as being associated with a poor outcome. This analysis will help to improve future international treatment planning and patient care of children with advanced AML.
Abstract: Successful management of relapse is critical to improve outcomes of children with acute myeloid leukemia (AML). We evaluated response, survival and prognostic factors after a second relapse of AML. Among 1222 pediatric patients of the population-based AML-Berlin–Frankfurt–Munster (BFM) study group (2004 until 2017), 73 patients met the quality parameters for inclusion in this study. Central review of source documentation warranted the accuracy of reported data. Treatment approaches included palliation in 17 patients (23%), intensive therapy with curative intent (n = 46, 63%) and other regimens (n = 10). Twenty-five patients (35%) received hematopoietic stem cell transplantation (HSCT), 21 of whom (88%) had a prior HSCT. Survival was poor, with a five-year probability of overall survival (pOS) of 15 ± 4% and 31 ± 9% following HSCT (n = 25). Early second relapse (within one year after first relapse) was associated with dismal outcome (pOS 2 ± 2%, n = 44 vs. 33 ± 9%, n = 29; p < 0.0001). A third complete remission (CR) is required for survival: 31% (n = 14) of patients with intensive treatment achieved a third CR with a pOS of 36 ± 13%, while 28 patients (62%) were non-responders (pOS 7 ± 5%). In conclusion, survival is poor but possible, particularly after a late second relapse and an intensive chemotherapy followed by HSCT. This analysis provides a baseline for future treatment planning.
Simple Summary: The incidence of brain metastases from breast cancer is increasing and the treatment is still a major challenge. Several scores have been developed in order to estimate the prognosis of patients with brain metastases by objective criteria. Here, we validated all three published graded-prognostic-assessment (GPA)-scores in a subcohort of 882 breast cancer patients with brain metastases in the Brain Metastases in the German Breast Cancer (BMBC) registry. Although all three available GPA-scores were associated with OS, they all show limitations mainly in predicting short-term (below 3 months) survival but also in long-term (above 12 months) survival. We discuss the test performances of all scores in our work and provide evidence how physicians should use them as a tool to select patients for different treatment options.
Abstract: Several scores have been developed in order to estimate the prognosis of patients with brain metastases (BM) by objective criteria. The aim of this analysis was to validate all three published graded-prognostic-assessment (GPA)-scores in a subcohort of 882 breast cancer (BC) patients with BM in the Brain Metastases in the German Breast Cancer (BMBC) registry. The median age at diagnosis of BM was 57 years. All in all, 22.3% of patients (n = 197) had triple-negative, 33.4% (n = 295) luminal A like, 25.1% (n = 221) luminal B/HER2-enriched like and 19.2% (n = 169) HER2 positive like BC. Age ≥60 years, evidence of extracranial metastases (ECM), higher number of BM, triple-negative subtype and low Karnofsky-Performance-Status (KPS) were all associated with worse overall survival (OS) in univariate analysis (p < 0.001 each). All three GPA-scores were associated with OS. The breast-GPA showed the highest probability of classifying patients with survival above 12 months in the best prognostic group (specificity 68.7% compared with 48.1% for the updated breast-GPA and 21.8% for the original GPA). Sensitivities for predicting 3 months survival were very low for all scores. In this analysis, all GPA-scores showed only moderate diagnostic accuracy in predicting the OS of BC patients with BM.
Shikonin reduces growth of docetaxel-resistant prostate cancer cells mainly through necroptosis
(2021)
Simple Summary: Prostate carcinoma (PCa) is the most common tumor in men with an increasing age-associated risk. Several therapy strategies, one of which is docetaxel (DX) chemotherapy, have been established. However, due to the development of therapy resistance, in which chemotherapy no longer effectively combats the cancer, advanced, metastasized PCa with a poor prognosis may become manifested and therapy inevitably fails. Thus, new treatment options are urgently needed. Shikonin (SHI), from Traditional Chinese Medicine, has revealed promising antitumor activity in several tumor entities. In the current study, the impact of SHI on four therapy-sensitive and four respective DX-resistant PCa cell lines was determined. SHI induced growth inhibition mainly by necroptosis, a type of cell death, in all the tested therapy-sensitive, but more importantly, DX-resistant PCa cell lines. Corresponding molecular alterations contributing to growth inhibition after SHI exposure were found. SHI could, therefore, be a promising additive in treating advanced PCa.
Abstract: The prognosis for advanced prostate carcinoma (PCa) remains poor due to development of therapy resistance, and new treatment options are needed. Shikonin (SHI) from Traditional Chinese Medicine has induced antitumor effects in diverse tumor entities, but data related to PCa are scarce. Therefore, the parental (=sensitive) and docetaxel (DX)-resistant PCa cell lines, PC3, DU145, LNCaP, and 22Rv1 were exposed to SHI [0.1–1.5 μM], and tumor cell growth, proliferation, cell cycling, cell death (apoptosis, necrosis, and necroptosis), and metabolic activity were evaluated. Correspondingly, the expression of regulating proteins was assessed. Exposure to SHI time- and dose-dependently inhibited tumor cell growth and proliferation in parental and DX-resistant PCa cells, accompanied by cell cycle arrest in the G2/M or S phase and modulation of cell cycle regulating proteins. SHI induced apoptosis and more dominantly necroptosis in both parental and DX-resistant PCa cells. This was shown by enhanced pRIP1 and pRIP3 expression and returned growth if applying the necroptosis inhibitor necrostatin-1. No SHI-induced alteration in metabolic activity of the PCa cells was detected. The significant antitumor effects induced by SHI to parental and DX-resistant PCa cells make the addition of SHI to standard therapy a promising treatment strategy for patients with advanced PCa.
Vascular biotransformation of organic nitrates is independent of cytochrome P450 monooxygenases
(2021)
Background and Purpose: Organic nitrates such as nitroglycerin (NTG) or pentaerythritol tetranitrate (PETN) have been used for over a century in the treatment of angina or ischaemic heart disease. These compounds are prodrugs which release their nitrovasodilators upon enzymic bioactivation by aldehyde dehydrogenase (ALDH2) or cytochromes P450 (CYP). Whereas ALDH2 is known to directly activate organic nitrates in vessels, the contribution of vascular CYPs is unknown and was studied here.
Experimental Approach: As all CYPs depend on cytochrome P450 reductase (POR) as electron donor, we generated a smooth muscle cell-specific, inducible knockout mouse of POR (smcPOR−/−) to investigate the contribution of POR/CYP to vascular biotransformation of organic nitrates.
Key Results: Microsomes containing recombinant CYPs expressed in human vascular tissues released nitrite from NTG and PETN with CYP2C9 and CYP2C8 being most efficient. SFK525, a CYP suicide inhibitor, blocked this effect. smcPOR−/− mice exhibited no obvious cardiovascular phenotype (normal cardiac weight and endothelium-dependent relaxation) and plasma and vascular nitrite production was similar to control (CTL) animals. NTG- and PETN-induced relaxation of isolated endothelium-intact or endothelium-denuded vessels were identical between CTL and smcPOR−/−. Likewise, nitrite release from organic nitrates in aortic rings was not affected by deletion of POR in smooth muscle cells (SMCs). In contrast, inhibition of ALDH2 by benomyl (10 μM) inhibited NTG-induced nitrite production and relaxation. Deletion of POR did not modulate this response.
Conclusions and Implications: Our data suggest that metabolism by vascular CYPs does not contribute to the pharmacological function of organic nitrates.
Parent ratings are often used for screening during the diagnostic evaluation of anxiety disorders. Clinically, it is important to correctly differentiate between anxiety and other psychiatric disorders and to distinguish specific anxiety disorders. The present study examined the validity of the screening results obtained by the Parent Questionnaire for Anxiety and Obsessive-Compulsive Disorders (FBB-ANZ). We exam- ined whether the FBB-ANZ discriminated (1) anxiety and other psychiatric disorders and (2) specific anxiety disorders in children and adoles- cents using ROC analyses. 972 parents of 4;00–11;11-year-old children and 12;00–17;11-year-old adolescents with anxiety disorders, depres- sive episodes, or externalizing disorders completed the FBB-ANZ. Discrimination of anxiety disorders and externalizing disorders in children (AUC = .72) and adolescents (AUC = .76) as well as depressive episodes in children (AUC = .77) was moderate. Good discrimination of different anxiety disorders was found only for separation anxiety in children (AUC = .84) and adolescents (AUC = .87). The results indicate the limited di- agnostic benefit of parent ratings for discriminating different anxiety disorders in children and adolescents. Potential explanations for the re- sults are critically discussed.
Lower leg fractures in children and adolescents - comparison of conservative vs. ECMES treatment
(2021)
Background: Lower leg fractures are one of the most common fractures in pediatric age. In general, treatment of lower leg fractures is predominantly non-operative, requiring clinical and radiological controls. Nevertheless, it can be observed that in recent years tibial shaft fractures have increasingly been treated surgically. The aim of the present study is to investigate treatment strategies in the context of different fracture types of the lower leg Methods: In this retrospective chart review, we analyzed 168 children with a diaphyseal fracture of the lower leg admitted to a trauma center between 2005 and 2017. The fractures were classified according to the AO Pediatric Comprehensive Classification of Long Bone Fractures (AO-PCCF). Results: The frequency of fractures based on the AO-PCCF classification was as follows: Simple oblique fracture of the tibia (43.5%, n = 73), hereof 32 toddler's fractures, multifragmentary oblique fracture of the tibia in 14.3% (n = 24) and simple oblique fracture of both, tibia and fibula in 18 patients (10.7%). Most pediatric fractures were treated conservatively by cast (n = 125). Thirty-seven patients received an ECMES, whereas 3 patients were treated with an external fixator and also 3 fractures were stabilized by plate osteosynthesis. Conservatively treated patients were significantly younger (mean age 6.0) compared to patients treated with ECMES (mean age 10.2) or plate osteosynthesis (PO)/external fixator (EF) (mean age 11.3), even if toddler's fractures (mean age 2.0) are excluded (mean age 7.4). There was no difference in time to full weight-bearing, hospitalization of patients treated with ECMES compared to conservative therapy although ECMES-treated fractures show more instability. The consolidation time was significantly higher in ECMES treated patients compared to conservative therapy. Conclusion: Pediatric patients (≤4 years) with lower leg fractures most often showed simple oblique fractures of the tibia, half of them toddler's fractures, which were treated predominantly by conservative therapy. All in all, the consolidation time was longer in intramedullary nailing (ECMES) than in conservative therapy. Nevertheless, time to full weight bearing and duration of cast was the same in both groups, even though ECMES treated fractures show more instability.
Background: The alpha7 nicotinic acetylcholine receptor (Chrna7) plays an essential anti-inflammatory role in immune homeostasis and was recently found on mast cells (MC). Psychosocial stress can trigger MC hyperactivation and increases pro-inflammatory cytokines in target tissues such as the skin. If the cholinergic system (CS) and Chrna7 ligands play a role in these cascades is largely unknown. Objective: To elucidate the role of the CS in the response to psychosocial stress using a mouse-model for stress-triggered cutaneous inflammatory circuits. Methods: Key CS markers (ACh, Ch, SLURP-1, SLURP-2, Lynx1, Chrm3, Chrna7, Chrna9, ChAT, VAChT, Oct3, AChE, and BChE) in skin and its MC (sMC), MC activation, immune parameters (TNFα, IL1β, IL10, TGFβ, HIF1α, and STAT3) and oxidative stress were analyzed in skin from 24 h noise-stressed mice and in cultured MC (cMC) from C57BL/6 or Chrna7-Knockout mice. Results: First, Chrna7 and SLURP-1 mRNA were exclusively upregulated in stressed skin. Second, histomorphometry located Chrna7 and SLURP-1 in nerves and sMC and demonstrated upregulated contacts and increased Chrna7+ sMC in stressed skin, while 5 ng/mL SLURP-1 degranulated cMC. Third, IL1β+ sMC were high in stressed skin, and while SLURP-1 alone had no significant effect on cMC cytokines, it upregulated IL1β in cMC from Chrna7-KO and in IL1β-treated wildtype cMC. In addition, HIF1α+ sMC were high in stressed skin and Chrna7-agonist AR-R 17779 induced ROS in cMC while SLURP-1 upregulated TNFα and IL1β in cMC when HIF1α was blocked. Conclusions: These data infer that the CS plays a role in the regulation of stress-sensitive inflammatory responses but may have a surprising pro-inflammatory effect in healthy skin, driving IL1β expression if SLURP-1 is involved.
Complement has been considered as an important factor impacting the host–pathogen association of spirochetes belonging to the Borrelia burgdorferi sensu lato complex, and may play a role in the spirochete’s ecology. Birds are known to be important hosts for ticks and in the maintenance of borreliae. Recent field surveys and laboratory transmission studies indicated that certain avian species act as reservoir hosts for different Borrelia species. Nevertheless, our current understanding of the molecular mechanisms determining host tropism of Borrelia is still in its fledgling stage. Concerning the role of complement in avian-host tropism, only a few bird species and Borrelia species have been analysed so far. Here, we performed in vitro serum bactericidal assays with serum samples collected from four bird species including the European robin Erithacus rubecula, the great tit Parus major, the Eurasian blackbird Turdus merula, and the racing pigeon Columba livia, as well as four Borrelia species (B. afzelii, B. garinii, B. valaisiana, and B. burgdorferi sensu stricto). From July to September 2019, juvenile wild birds were caught using mist nets in Portugal. Racing pigeons were sampled in a loft in October 2019. Independent of the bird species analysed, all Borrelia species displayed an intermediate serum-resistant or serum-resistant phenotype except for B. afzelii challenged with serum from blackbirds. This genospecies was efficiently killed by avian complement, suggesting that blackbirds served as dead-end hosts for B. afzelii. In summary, these findings suggest that complement contributes in the avian–spirochete–tick infection cycle and in Borrelia-host tropism.
Background: To investigate patients’ perspectives on polypharmacy and the use of a digital decision support system to assist general practitioners (GPs) in performing medication reviews. Methods: Qualitative interviews with patients or informal caregivers recruited from participants in a cluster-randomized controlled clinical trial (cRCT). The interviews were transcribed verbatim and analyzed using thematic analysis. Results: We conducted 13 interviews and identified the following seven themes: the patients successfully integrated medication use in their everyday lives, used medication plans, had both good and bad personal experiences with their drugs, regarded their healthcare providers as the main source of medication-related information, discussed medication changes with their GPs, had trusting relationships with them, and viewed the use of digital decision support tools for medication reviews positively. No unwanted adverse effects were reported. Conclusions: Despite drug-related problems, patients appeared to cope well with their medications. They also trusted their GPs, despite acknowledging polypharmacy to be a complex field for them. The use of a digital support system was appreciated and linked to the hope that reasons for selecting specific medication regimens would become more comprehensible. Further research with a more diverse sampling might add more patient perspectives.
Background: To assess the potential of radiomic features to quantify components of blood in intraaortic vessels to non-invasively predict moderate-to-severe anemia in non-contrast enhanced CT scans. Methods: One hundred patients (median age, 69 years; range, 19–94 years) who received CT scans of the thoracolumbar spine and blood-testing for hemoglobin and hematocrit levels ± 24 h between 08/2018 and 11/2019 were retrospectively included. Intraaortic blood was segmented using a spherical volume of interest of 1 cm diameter with consecutive radiomic analysis applying PyRadiomics software. Feature selection was performed applying analysis of correlation and collinearity. The final feature set was obtained to differentiate moderate-to-severe anemia. Random forest machine learning was applied and predictive performance was assessed. A decision-tree was obtained to propose a cut-off value of CT Hounsfield units (HU). Results: High correlation with hemoglobin and hematocrit levels was shown for first-order radiomic features (p < 0.001 to p = 0.032). The top 3 features showed high correlation to hemoglobin values (p) and minimal collinearity (r) to the top ranked feature Median (p < 0.001), Energy (p = 0.002, r = 0.387), Minimum (p = 0.032, r = 0.437). Median (p < 0.001) and Minimum (p = 0.003) differed in moderate-to-severe anemia compared to non-anemic state. Median yielded superiority to the combination of Median and Minimum (p(AUC) = 0.015, p(precision) = 0.017, p(accuracy) = 0.612) in the predictive performance employing random forest analysis. A Median HU value ≤ 36.5 indicated moderate-to-severe anemia (accuracy = 0.90, precision = 0.80). Conclusions: First-order radiomic features correlate with hemoglobin levels and may be feasible for the prediction of moderate-to-severe anemia. High dimensional radiomic features did not aid augmenting the data in our exemplary use case of intraluminal blood component assessment.
Exploring mechanisms of drug resistance to targeted small molecule drugs is critical for an extended clinical benefit in the treatment of non-small cell lung cancer (NSCLC) patients carrying activating epidermal growth factor receptor (EGFR) mutations. Here, we identified constitutive cell proliferation regulating inhibitor of protein phosphatase 2A (CIP2A) in the HCC4006rErlo0.5 NSCLC cell line adapted to erlotinib as a model of acquired drug resistance. Constitutive CIP2A resulted in a constitutive activation of Akt signaling. The proteasome inhibitor bortezomib was able to reduce CIP2A levels, which resulted in an activation of protein phosphatase 2A and deactivation of Akt. Combination experiments with erlotinib and bortezomib revealed a lack of interaction between the two drugs. However, the effect size of bortezomib was higher in HCC4006rErlo0.5, compared to the erlotinib-sensitive HCC4006 cells, as indicated by an increase in Emax (0.911 (95%CI 0.867–0.954) vs. 0.585 (95%CI 0.568–0.622), respectively) and decrease in EC50 (52.4 µM (95%CI 46.1–58.8 µM) vs. 73.0 µM (95%CI 60.4–111 µM), respectively) in the concentration–effect model, an earlier onset of cell death induction, and a reduced colony surviving fraction (0.38 ± 0.18 vs. 0.95 ± 0.25, respectively, n = 3, p < 0.05). Therefore, modulation of CIP2A with bortezomib could be an interesting approach to overcome drug resistance to erlotinib treatment in NSCLC.
Background: Since there is no standardized and effective treatment for advanced uveal melanoma (UM), the prognosis is dismal once metastases develop. Due to the availability of immune checkpoint blockade (ICB) in the real-world setting, the prognosis of metastatic UM has improved. However, it is unclear how the presence of hepatic and extrahepatic metastasis impacts the response and survival after ICB. Methods: A total of 178 patients with metastatic UM treated with ICB were included in this analysis. Patients were recruited from German skin cancer centers and the German national skin cancer registry (ADOReg). To investigate the impact of hepatic metastasis, two cohorts were compared: patients with liver metastasis only (cohort A, n = 55) versus those with both liver and extra-hepatic metastasis (cohort B, n = 123). Data were analyzed in both cohorts for response to treatment, progression-free survival (PFS), and overall survival (OS). The survival and progression probabilities were calculated with the Kaplan–Meier method. Log-rank tests, χ2 tests, and t-tests were performed to detect significant differences between both cohorts. Results: The median OS of the overall population was 16 months (95% CI 13.4–23.7) and the median PFS, 2.8 months (95% CI 2.5–3.0). The median OS was longer in cohort B than in cohort A (18.2 vs. 6.1 months; p = 0.071). The best objective response rate to dual ICB was 13.8% and to anti-PD-1 monotherapy 8.9% in the entire population. Patients with liver metastases only had a lower response to dual ICB, yet without significance (cohort A 8.7% vs. cohort B 16.7%; p = 0.45). Adverse events (AE) occurred in 41.6%. Severe AE were observed in 26.3% and evenly distributed between both cohorts. Conclusion: The survival of this large cohort of patients with advanced UM was more favorable than reported in previous benchmark studies. Patients with both hepatic and extrahepatic metastasis showed more favorable survival and higher response to dual ICB than those with hepatic metastasis only.
Treatment options of locoregional recurrent head and neck squamous cell cancer (HNSCC) include both local strategies as surgery or re-radiotherapy and systemic therapy. In this prospective, multi-center, non-interventional study, patients were treated either with platinum-based chemotherapy and cetuximab (CT + Cet) or re-radiotherapy and cetuximab (RT + Cet). In the current analysis, progression-free survival (PFS) and overall survival (OS) were compared in patients with locoregional recurrence. Four hundred seventy patients were registered in 97 German centers. After exclusion of patients with distant metastases, a cohort of 192 patients was analyzed (129 CT + Cet, 63 RT + Cet). Radiotherapy was delivered as re-irradiation to 70% of the patients. The mean radiation dose was 51.8 Gy, whereas a radiation dose of ≥60 Gy was delivered in 33% of the patients. Chemotherapy mainly consisted of cisplatin/5-flurouracil (40%) or carboplatin/5-flurouracil (29%). The median PFS was 9.2 months in the RT + Cet group versus 5.1 months in the CT + Cet group (hazard ratio for disease progression or death, 0.40, 95% CI, 0.27–0.57, p < 0.0001). Median OS was 12.8 months in the RT + Cet group versus 7.9 months in the CT + Cet group (hazard ratio for death, 0.50, 95% CI, 0.33–0.75, p = 0.0008). In conclusion, radiotherapy combined with cetuximab improved survival compared to chemotherapy combined with cetuximab in locally recurrent HNSCC.
Medulloblastoma is a rare brain malignancy. Patients after puberty are rare and bear an intermediate prognosis. Standard treatment consists of maximal resection plus radio-chemotherapy. Treatment toxicity is high and produces disabling long-term side effects. The sonic hedgehog (SHH) subgroup is highly overrepresented in the post-pubertal and adult population and can be targeted by smoothened (SMO) inhibitors. No practice-changing prospective randomized data have been generated in adults. The EORTC 1634-BTG/NOA-23 trial will randomize patients between standard-dose vs. reduced-dosed craniospinal radiotherapy and SHH-subgroup patients between the SMO inhibitor sonidegib (OdomzoTM, Sun Pharmaceuticals Industries, Inc., New York, USA) in addition to standard radio-chemotherapy vs. standard radio-chemotherapy alone to improve outcomes in view of decreased radiotherapy-related toxicity and increased efficacy. We will further investigate tumor tissue, blood, and cerebrospinal fluid as well as magnetic resonance imaging and radiotherapy plans to generate information that helps to further improve treatment outcomes. Given that treatment side effects typically occur late, long-term follow-up will monitor classic side effects of therapy, but also health-related quality of life, cognition, social and professional outcome, and reproduction and fertility. In summary, we will generate unprecedented data that will be translated into treatment changes in post-pubertal patients with medulloblastoma and will help to design future clinical trials.
Background: A major disadvantage of current spacers for two-stage revision total knee arthroplasty (R-TKA) is the risk of (sub-) luxation during mobilization in the prosthesis-free interval, limiting their clinical success with detrimental consequences for the patient. The present study introduces a novel inverse spacer, which prevents major complications, such as spacer (sub-) luxations and/or fractures of spacer or bone. Methods: The hand-made inverse spacer consisted of convex tibial and concave femoral components of polymethylmethacrylate bone cement and was intra-operatively molded under maximum longitudinal tension in 5° flexion and 5° valgus position. Both components were equipped with a stem for rotational stability. This spacer was implanted during an R-TKA in 110 knees with diagnosed or suspected periprosthetic infection. Postoperative therapy included a straight leg brace and physiotherapist-guided, crutch-supported mobilization with full sole contact. X-rays were taken before and after prosthesis removal and re-implantation. Results: None of the patients experienced (sub-) luxations/fractures of the spacer, periprosthetic fractures, or soft tissue compromise requiring reoperation. All patients were successfully re-implanted after a prosthesis-free interval of 8 weeks, except for three patients requiring an early exchange of the spacer due to persisting infection. In these cases, the prosthetic-free interval was prolonged for one week. Conclusion: The inverse spacer in conjunction with our routine procedure is a safe and cost-effective alternative to other articulating or static spacers, and allows crutch-supported sole contact mobilization without major post-operative complications. Maximum longitudinal intra-operative tension in 5° flexion and 5° valgus position appears crucial for the success of surgery.
Background: Clinical practice guidelines for patients with primary biliary cholangitis (PBC) have been recently revised and implemented for well-established response criteria to standard first-line ursodeoxycholic acid (UDCA) therapy at 12 months after treatment initiation for the early identification of high-risk patients with inadequate treatment responses who may require treatment modification. However, there are only very limited data concerning the real-world clinical management of patients with PBC in Germany. Objective: The aim of this retrospective multicenter study was to evaluate response rates to standard first-line UDCA therapy and subsequent Second-line treatment regimens in a large cohort of well-characterized patients with PBC from 10 independent hepatological referral centers in Germany prior to the introduction of obeticholic acid as a licensed second-line treatment option. Methods: Diagnostic confirmation of PBC, standard first-line UDCA treatment regimens and response rates at 12 months according to Paris-I, Paris-II, and Barcelona criteria, the follow-up cut-off alkaline phosphatase (ALP) ≤ 1.67 × upper limit of normal (ULN) and the normalization of bilirubin (bilirubin ≤ 1 × ULN) were retrospectively examined between June 1986 and March 2017. The management and hitherto applied second-line treatment regimens in patients with an inadequate response to UDCA and subsequent response rates at 12 months were also evaluated. Results: Overall, 480 PBC patients were included in this study. The median UDCA dosage was 13.2 mg UDCA/kg bodyweight (BW)/d. Adequate UDCA treatment response rates according to Paris-I, Paris-II, and Barcelona criteria were observed in 91, 71.3, and 61.3% of patients, respectively. In 83.8% of patients, ALP ≤ 1.67 × ULN were achieved. A total of 116 patients (24.2%) showed an inadequate response to UDCA according to at least one criterion. The diverse second-line treatment regimens applied led to significantly higher response rates according to Paris-II (35 vs. 60%, p = 0.005), Barcelona (13 vs. 34%, p = 0.0005), ALP ≤ 1.67 × ULN and bilirubin ≤ 1 × ULN (52.1 vs. 75%, p = 0.002). The addition of bezafibrates appeared to induce the strongest beneficial effect in this cohort (Paris II: 24 vs. 74%, p = 0.004; Barcelona: 50 vs. 84%, p = 0.046; ALP < 1.67 × ULN and bilirubin ≤ 1 × ULN: 33 vs. 86%, p = 0.001). Conclusion: Our large retrospective multicenter study confirms high response rates following UDCA first-line standard treatment in patients with PBC and highlights the need for close monitoring and early treatment modification in high-risk patients with an insufficient response to UDCA since early treatment modification significantly increases subsequent response rates of these patients.
Bloodstream infections (BSI) are a severe complication of antineoplastic chemotherapy or hematopoietic stem cell transplantation (HSCT), especially in the presence of antibiotic resistance (AR). A multinational, multicenter retrospective study in patients aged ≤ 18 years, treated with chemotherapy or HSCT from 2015 to 2017 was implemented to analyze AR among non-common skin commensals BSI. Risk factors associated with AR, intensive care unit (ICU) admission and mortality were analyzed by multilevel mixed effects or standard logistic regressions. A total of 1291 BSIs with 1379 strains were reported in 1031 patients. Among Gram-negatives more than 20% were resistant to ceftazidime, cefepime, piperacillin-tazobactam and ciprofloxacin while 9% was resistant to meropenem. Methicillin-resistance was observed in 17% of S. aureus and vancomycin resistance in 40% of E. faecium. Previous exposure to antibiotics, especially to carbapenems, was significantly associated with resistant Gram-negative BSI while previous colonization with methicillin-resistant S. aureus was associated with BSI due to this pathogen. Hematological malignancies, neutropenia and Gram-negatives resistant to >3 antibiotics were significantly associated with higher risk of ICU admission. Underlying disease in relapse/progression, previous exposure to antibiotics, and need of ICU admission were significantly associated with mortality. Center-level variation showed a greater impact on AR, while patient-level variation had more effect on ICU admission and mortality. Previous exposure to antibiotics or colonization by resistant pathogens can be the cause of AR BSI. Resistant Gram-negatives are significantly associated with ICU admission and mortality, with a significant role for the treating center too. The significant evidence of center-level variations on AR, ICU admission and mortality, stress the need for careful local antibiotic stewardship and infection control programs.
Simple Summary: Tooth roots are increasingly applied for bone reconstruction before implant placement. Growth factors stored in the dentin are assumed to enhance bone regeneration, however, the evidence is low. To this aim, collagen membranes were coated with dentin lysates obtained from extracted porcine teeth or remain untreated. The collagen membranes were tested for their capacity to stimulate bone formation in rat calvarial bone defects. After four weeks of healing, micro-computed tomography and histological analyses revealed that dentin lysates coating had no significant impact on the rather strong bone regeneration reaching a nearly complete defect closure even in untreated defects. It can thus be concluded that dentin lysates do not hinder bone regeneration. Conclusions concerning a possible stimulation of bone regeneration by dentin lysates should not be drawn.
Abstract: Autogenous tooth roots are increasingly applied as a grafting material in alveolar bone augmentation. Since tooth roots undergo creeping substitution similar to bone grafts, it can be hypothesized that osteoclasts release the growth factors stored in the dentin thereby influencing bone formation. To test this hypothesis, collagen membranes were either soaked in acid dentin lysates (ADL) from extracted porcine teeth or serum–free medium followed by lyophilization. Thereafter, these membranes covered standardized 5-mm-diameter critical-size defects in calvarial bone on rats. After four weeks of healing, micro-computed tomography and histological analyses using undecalcified thin ground sections were performed. Micro-computed tomography of the inner 4.5 mm calvaria defects revealed a median bone defect coverage of 91% (CI: 87–95) in the ADL group and 94% (CI: 65–100) in the control group, without significant differences between the groups (intergroup p > 0.05). Furthermore, bone volume (BV) was similar between ADL group (5.7 mm3, CI: 3.4–7.1) and control group (5.7 mm3, CI: 2.9–9.7). Histomorphometry of the defect area confirmed these findings with bone area values amounting to 2.1 mm2 (CI: 1.2–2.6) in the ADL group and 2.0 mm2 (CI: 1.1–3.0) in the control group. Together, these data suggest that acid dentin lysate lyophilized onto collagen membranes failed to modulate the robust bone formation when placed onto calvarial defects.
The rapid detection of pathogens in infected wounds can significantly improve the clinical outcome. Wound exudate, which can be collected in a non-invasive way, offers an attractive sample material for the detection of pathogens at the point-of-care (POC). Here, we report the development of a nucleic acid lateral flow immunoassay for direct detection of isothermally amplified DNA combined with fast sample preparation. The streamlined protocol was evaluated using human wound exudate spiked with the opportunistic pathogen Pseudomonas aeruginosa that cause severe health issues upon wound colonization. A detection limit of 2.1 × 105 CFU per mL of wound fluid was achieved, and no cross-reaction with other pathogens was observed. Furthermore, we integrated an internal amplification control that excludes false negative results and, in combination with the flow control, ensures the validity of the test result. The paper-based approach with only three simple hands-on steps has a turn-around time of less than 30 min and covers the complete analytical process chain from sample to answer. This newly developed workflow for wound fluid diagnostics has tremendous potential for reliable pathogen POC testing and subsequent target-oriented therapy.
Causality assessment in liver injury induced by drugs and herbs remains a debated issue, requiring innovation and thorough understanding based on detailed information. Artificial intelligence (AI) principles recommend the use of algorithms for solving complex processes and are included in the diagnostic algorithm of Roussel Uclaf Causality Assessment Method (RUCAM) to help assess causality in suspected cases of idiosyncratic drug-induced liver injury (DILI) and herb-induced liver injury (HILI). From 1993 until the middle of 2020, a total of 95,865 DILI and HILI cases were assessed by RUCAM, outperforming by case numbers any other causality assessment method. The success of RUCAM can be traced back to its quantitative features with specific data elements that are individually scored leading to a final causality grading. RUCAM is objective, user friendly, transparent, and liver injury specific, with an updated version that should be used in future DILI and HILI cases. Support of RUCAM was also provided by scientists from China, not affiliated to any network, in the results of a scientometric evaluation of the global knowledge base of DILI. They highlighted the original RUCAM of 1993 and their authors as a publication quoted the greatest number of times and ranked first in the category of the top 10 references related to DILI. In conclusion, for stakeholders involved in DILI and HILI, RUCAM seems to be an effective diagnostic algorithm in line with AI principles.
The aim of this study was to evaluate the clinical and microbiological effects of subgingival instrumentation (SI) alone or combined with either local drug delivery (LDD) or photodynamic therapy (PDT) in persistent/recurrent pockets in patients enrolled in supportive periodontal therapy (SPT). A total of 105 patients enrolled in SPT were randomly treated as follows: group A (n = 35): SI +PDT and 7 days later 2nd PDT; group B (n = 35): SI+LDD; group C (n = 35): SI (control). Prior intervention, at 3 and 6 months after therapy, probing pocket depths, clinical attachment level, number of treated sites with bleeding on probing (n BOP), full mouth plaque and bleeding scores (gingival bleeding index, %BOP) were recorded. At the same time points, 8 periodontopathogens were quantitatively determined. All three treatments resulted in statistically significant improvements (p < 0.05) of all clinical parameters without statistically significant intergroup differences (p > 0.05). Several bacterial species were reduced in both test groups, with statistically significantly higher reductions for LDD compared to PDT and the control group. In conclusion, the present data indicate that: (a) In periodontal patients enrolled in SPT, treatment of persistent/recurrent pockets with SI alone or combined with either PDT or LDD may lead to comparable clinical improvements and (b) the adjunctive use of LDD appears to provide better microbiological improvements for some periodontal pathogens than SI alone or combined with PDT.
Simple Summary: Renal insufficiency is frequently seen in newly diagnosed multiple myeloma and can be due to the disease itself but also caused by medical interventions or infections. Patients with severe renal insufficiency are known to have an adverse prognosis, but recently, it was shown that even moderately impaired kidney function can have long-term sequelae. Achieving quick disease control by effective antimyeloma therapy can lead to the recovery of renal function. We investigated the kidney-specific variables in a large cohort of 770 myeloma patients receiving three different three-drug regimens for initial myeloma treatment to learn more about the differential effects on kidney function in an early disease phase. All regimens had a positive impact on kidney function without a difference in the proportion of patients who reached normal renal function after three cycles. Interestingly, patients who received bortezomib, lenalidomide, and dexamethasone tended to have higher risk for a worse renal function following induction when compared to the initial values.
Abstract: Background: Preservation of kidney function in newly diagnosed (ND) multiple myeloma (MM) helps to prevent excess toxicity. Patients (pts) from two prospective trials were analyzed, provided postinduction (PInd) restaging was performed. Pts received three cycles with bortezomib (btz), cyclophosphamide, and dexamethasone (dex; VCD) or btz, lenalidomide (len), and dex (VRd) or len, adriamycin, and dex (RAD). The minimum required estimated glomerular filtration rate (eGFR) was >30 mL/min. We analyzed the percent change of the renal function using the International Myeloma Working Group (IMWG) criteria and Kidney Disease: Improving Global Outcomes (KDIGO)-defined categories. Results: Seven hundred and seventy-two patients were eligible. Three hundred and fifty-six received VCD, 214 VRd, and 202 RAD. VCD patients had the best baseline eGFR. The proportion of pts with eGFR <45 mL/min decreased from 7.3% at baseline to 1.9% PInd (p < 0.0001). Thirty-seven point one percent of VCD versus 49% of VRd patients had a decrease of GFR (p = 0.0872). IMWG-defined “renal complete response (CRrenal)” was achieved in 17/25 (68%) pts after VCD, 12/19 (63%) after RAD, and 14/27 (52%) after VRd (p = 0.4747). Conclusions: Analyzing a large and representative newly diagnosed myeloma (NDMM) group, we found no difference in CRrenal that occurred independently from the myeloma response across the three regimens. A trend towards deterioration of the renal function with VRd versus VCD may be explained by a better pretreatment “renal fitness” in the latter group.
Simple Summary: Forensic entomologists are most often tasked with determining when arthropods colonized living or deceased vertebrates. In most cases, this estimation involves humans; however, pets, livestock, and other domesticated animals can also be illegally killed or victims of neglect. Globally, there is no standard format for the case report, and much of the content is based on the personal preferences of the analyst or standards set within a country. The article below proposes a general overview of sections to be considered when drafting a case report.
Abstract: Forensic practitioners analyzing entomological evidence are faced with numerous challenges when presenting their findings to law practitioners, particularly in terms of terminology used to describe insect age, what this means for colonization time of remains, and the limitations to estimates made. Due to varying legal requirements in different countries, there is no standard format for the entomological case report prepared, nor any guidelines as to the sections that are required, optional or unnecessary in a case report. The authors herein propose sections that should be considered when drafting an entomological case report. The criteria under which entomological evidence is analyzed are discussed, as well as the limitations for each criterion. The concept of a global, standardized entomological case report is impossible to achieve due to national legislative differences, but the authors here propose a basic template which can be adapted and changed according to the needs of the practitioner. Furthermore, while the discussion is fairly detailed, capturing all differences between nations could not be accomplished, and those initiating casework for the first time are encouraged to engage other practicing forensic entomologists or professional associations within their own nation or region, to ensure a complete report is generated that meets lab or national requirements, prior to generating a finalized report.
Tumor antigen-specific redirection of cytotoxic T cells (CTLs) or natural killer (NK) cells including chimeric antigen receptor (CAR-) and T cell receptor (TCR-) cell therapy is currently being evaluated in different tumor entities including melanoma. Expression of melanoma-specific antigen recognized by the respective CAR or TCR directly or presented by HLA molecules is an indispensable prerequisite for this innovative therapy. In this study, we investigated in 168 FFPE tumor specimens of patients with stage I-IV melanoma the protein expression of HER2, TRP2, ABCB5, gp100, p53, and GD2 by immunohistochemistry (IHC). These results were correlated with clinical parameters. Membrane expression of HER2 and GD2 was also investigated in ten melanoma cell lines by flow cytometry for which corresponding tumors were analyzed by IHC. Our results demonstrated that gp100 was the most frequently overexpressed protein (61%), followed by TRP2 (50%), GD2 (38%), p53 (37%), ABCB5 (17%), and HER2 (3%). TRP2 expression was higher in primary tumors compared to metastases (p = 0.005). Accordingly, TRP2 and ABCB5 expression was significantly associated with lower tumor thickness of the primary (p = 0.013 and p = 0.025). There was no association between protein expression levels and survival in advanced melanoma patients. Flow cytometric analysis revealed abundant surface expression of GD2 and HER2 in all melanoma cell lines. The discordant HER2 expression in situ and in vitro suggests a tissue culture associated induction. In summary, our data support the use of gp100 and GD2 as a potential target for developing engineered TCR- or CAR-cell therapies, respectively, against melanoma.
Simple Summary: Currently, it is unclear which kind of axillary staging surgery breast cancer patients with lymph node metastasis should receive after neoadjuvant chemotherapy. For decades, these patients have been treated with a full axillary lymph node dissection, even if they converted to clinical node negativity. However, the removal of a large number of lymph nodes during the procedure can increase arm morbidity and impact quality of life. Therefore, several studies investigated less radical surgical strategies in this setting, such as sentinel lymph node biopsy or targeted axillary dissection, i.e., removal of a previously marked node combined with sentinel node removal. In this review, we summarize current evidence on the different surgical techniques and compare national and international recommendations. We show that many questions regarding oncological safety of different surgery types and the optimal marking technique remain unanswered and present the multinational prospective cohort study AXSANA that will address these open issues.
Abstract: In the last two decades, surgical methods for axillary staging in breast cancer patients have become less extensive, and full axillary lymph node dissection (ALND) is confined to selected patients. In initially node-positive patients undergoing neoadjuvant chemotherapy, however, the optimal management remains unclear. Current guidelines vary widely, endorsing different strategies. We performed a literature review on axillary staging strategies and their place in international recommendations. This overview defines knowledge gaps associated with specific procedures, summarizes currently ongoing clinical trials that address these unsolved issues, and provides the rationale for further research. While some guidelines have already implemented surgical de-escalation, replacing ALND with, e.g., sentinel lymph node biopsy (SLNB) or targeted axillary dissection (TAD) in cN+ patients converting to clinical node negativity, others recommend ALND. Numerous techniques are in use for tagging lymph node metastasis, but many questions regarding the marking technique, i.e., the optimal time for marker placement and the number of marked nodes, remain unanswered. The optimal number of SLNs to be excised also remains a matter of debate. Data on oncological safety and quality of life following different staging procedures are lacking. These results provide the rationale for the multinational prospective cohort study AXSANA initiated by EUBREAST, which started enrollment in June 2020 and aims at recruiting 3000 patients in 20 countries (NCT04373655; Funded by AGO-B, Claudia von Schilling Foundation for Breast Cancer Research, AWOgyn, EndoMag, Mammotome, and MeritMedical).
The pathophysiological role of neural autoantibodies in acute psychotic disorders is receiving increased attention. However, there is still an ongoing debate, whether predominantly psychotic manifestations of autoimmune encephalitides exist that may remain undetected and, thus, untreated. Furthermore, it is discussed if such conditions can be diagnosed based on serum antibody results or if a reliable diagnosis requires additional cerebrospinal fluids (CSF) results. In this study, we screened pairs of serum and CSF samples from antipsychotic-naïve individuals with first-episode schizophrenic psychosis (FEP, n = 103), clinical high risk for psychosis (CHR, n = 47), and healthy volunteers (HV, n = 40) for eight different antibodies against various antigens that have been shown to be associated with autoimmune encephalitides: N-methyl-D-aspartate receptor (NMDAR, NR1 subunits only), glutamic acid decarboxylase (GAD65), leucine-rich glioma inactivated protein 1 (LGI1), contactin-associated protein-like 2 protein (CASPR2), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) subunit 1, AMPAR subunit 2, γ-aminobutyric acid-B receptors (GABABR), and glycine receptors. All patients were within the norm with regards to a careful neurological examination, a magnetic resonance imaging (MRI) of the brain, an electroencephalogram (EEG), and routine blood pathology. All CSF samples were autoantibody-negative. In three serum samples of individuals with FEP, we detected low-titer CASPR2 immunoglobulin (Ig) G antibodies (≤1:160, n = 2) and non-IgG antibodies against NMDAR (n = 1) (overall serum-autoantibody prevalence in FEP: 2.91%). However, the IgG titers were below the laboratory cut-off defined for positivity, and non-IgG antibodies are of no clinical relevance. This suggests that there were no cases of autoimmune encephalitis in our cohort. Our results highlight the importance and the high specificity of CSF analysis to reliably detect autoantibodies. They confirm the hypothesis that pure psychotic manifestations of antibody-associated autoimmune encephalitides without any additional neuropsychiatric findings are very rare. However, special attention must be paid to those presenting with atypical mental illnesses with additional neurological symptoms, evidence of clinically-significant cognitive involvement, profound sleep-wake perturbations, seizures, electroencephalographic, or magnetic resonance imaging pathologies to be able to identify cases with autoimmune-mediated psychiatric syndromes.
Background: Treatment of first-time shoulder dislocation (FSD) is a topic of debate. After high rates of recurrent instability after nonoperative management were reported in the literature, primary repair of FSD significantly increased. At the same time, new concepts were proposed that had promising results for immobilization in external rotation (ER) and abduction (ABD). Purpose: The aim of this study was to evaluate the recurrence rates (primary outcome) and clinical outcomes (secondary outcome parameters) of immobilization in ER+ABD versus arthroscopic primary stabilization after FSD. Study Design: Randomized controlled trial; Level of evidence, 1. Methods: In a multicenter randomized controlled trial, patients with FSD were randomized to either treatment with immobilization in 60° of ER plus 30° of ABD (group 1) or surgical treatment with arthroscopic Bankart repair (group 2). Clinical evaluation was performed 1, 3, and 6 weeks as well as 6, 12, and 24 months postoperatively or after reduction, including range of motion, instability testing, subjective shoulder value, Constant-Murley score, Rowe score, and Western Ontario Shoulder Instability Index. Recurrent instability events were prospectively recorded. Results: Between 2011 and 2017, a total of 112 patients were included in this study. Of these, 60 patients were allocated to group 1 and 52 to group 2. At the 24-month follow-up, 91 patients (81.3%) were available for clinical examination. The recurrence rate was 19.1% in group 1 and 2.3% in group 2 (P = .016). No significant differences were found between groups regarding clinical shoulder scores (P > .05). Due to noncompliance with the immobilization treatment protocol, 4 patients (6.7%) were excluded. Conclusion: Immobilization in ER+ABD versus primary arthroscopic shoulder stabilization for the treatment of FSD showed no differences in clinical shoulder scores. However, recurrent instability was significantly higher after nonoperative treatment.
Background: Gan–Dou–Fu–Mu decoction (GDFMD) improves liver fibrosis in experimental and clinical studies including those on toxic mouse model of Wilson disease (Model). However, the mechanisms underlying the effect of GDFMD have not been characterized. Herein, we deciphered the potential therapeutic targets of GDFMD using transcriptome analysis.
Methods: We constructed a tx-j Wilson disease (WD) mouse model, and assessed the effect of GDFMD on the liver of model mice by hematoxylin and eosin, Masson, and immunohistochemical staining. Subsequently, we identified differentially expressed genes (DEGs) that were upregulated in the Model (Model vs. control) and those that were downregulated upon GDFMD treatment (compared to the Model) using RNA-sequencing (RNA-Seq). Biological functions and signaling pathways in which the DEGs were involved were determined by gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) pathway analyses. A protein–protein interaction (PPI) network was constructed using the STRING database, and the modules were identified using MCODE plugin with the Cytoscape software. Several genes identified in the RNA-Seq analysis were validated by real-time quantitative PCR. Results: Total of 2124 DEGs were screened through the Model vs. control and Model vs. GDFMD comparisons, and dozens of GO and KEGG pathway terms modulated by GDFMD were identified. Dozens of pathways involved in metabolism (including metabolic processes for organic acids, carboxylic acids, monocarboxylic acids, lipids, fatty acids, cellular lipids, steroids, alcohols, eicosanoids, long-chain fatty acids), immune and inflammatory response (such as complement and coagulation cascades, cytokine–cytokine receptor interaction, inflammatory mediator regulation of TRP channels, antigen processing and presentation, T-cell receptor signaling pathway), liver fibrosis (such as ECM-receptor interactions), and cell death (PI3K-Akt signaling pathway, apoptosis, TGF-beta signaling pathway, etc.) were identified as potential targets of GDFMD in the Model. Some hub genes and four modules were identified in the PPI network. The results of real-time quantitative PCR analysis were consistent with those of RNA-Seq analysis. Conclusions: We performed gene expression profiling of GDFMD-treated WD model mice using RNA-Seq analysis and found the genes, pathways, and processes effected by the treatment. Our study provides a theoretical basis to prevent liver fibrosis resulting from WD using GDFMD.
Simple Summary: Mutations in RAS-family genes frequently cause different types of human cancers. Inhibitors of the MEK (mitogen-activated protein kinase) and ERK (extracellular signal-regulated kinase) protein kinases that function downstream of RAS proteins have shown some clinical benefits when used for the treatment of these cancers, but drug resistance frequently emerges. Here we show that combined treatment with MEK and ERK inhibitors blocks the emergence of resistance to either drug alone. However, if cancer cells have already developed resistance to MEK inhibitors or to ERK inhibitors, the combined therapy is frequently ineffective. These findings imply that these inhibitors should be used together for cancer therapy. We also show that drug resistance involves complex patterns of rewiring of cellular kinase signaling networks that do not overlap between each different cancer cell line. Nonetheless, we show that MAP4K4 is required for efficient cell proliferation in several different MEK/ERK inhibitor resistant cancer cell lines, uncovering a potential new therapeutic target.
Abstract: Oncogenic mutations in RAS family genes arise frequently in metastatic human cancers. Here we developed new mouse and cellular models of oncogenic HrasG12V-driven undifferentiated pleomorphic sarcoma metastasis and of KrasG12D-driven pancreatic ductal adenocarcinoma metastasis. Through analyses of these cells and of human oncogenic KRAS-, NRAS- and BRAF-driven cancer cell lines we identified that resistance to single MEK inhibitor and ERK inhibitor treatments arise rapidly but combination therapy completely blocks the emergence of resistance. The prior evolution of resistance to either single agent frequently leads to resistance to dual treatment. Dual MEK inhibitor plus ERK inhibitor therapy shows anti-tumor efficacy in an HrasG12V-driven autochthonous sarcoma model but features of drug resistance in vivo were also evident. Array-based kinome activity profiling revealed an absence of common patterns of signaling rewiring in single or double MEK and ERK inhibitor resistant cells, showing that the development of resistance to downstream signaling inhibition in oncogenic RAS-driven tumors represents a heterogeneous process. Nonetheless, in some single and double MEK and ERK inhibitor resistant cell lines we identified newly acquired drug sensitivities. These may represent additional therapeutic targets in oncogenic RAS-driven tumors and provide general proof-of-principle that therapeutic vulnerabilities of drug resistant cells can be identified.
Neurogenic/neuropathic bowel dysfunction (NBD) is common in children who are affected by congenital and acquired neurological disease, and negatively impacts quality of life. In the past, NBD received less attention than neurogenic bladder, generally being considered only in spina bifida (the most common cause of pediatric NBD). Many methods of conservative and medical management of NBD are reported, including relatively recently Transanal Irrigation (TAI). Based on the literature and personal experience, an expert group (pediatric urologists/surgeons/gastroenterologists with specific experience in NBD) focused on NBD in children and adolescents. A statement document was created using a modified Delphi method. The range of causes of pediatric NBD are discussed in this paper. The various therapeutic approaches are presented to improve clinical management. The population of children and adolescents with NBD is increasing, due both to the higher survival rate and better diagnosis. While NBD is relatively predictable in producing either constipation or fecal incontinence, or both, its various effects on each patient will depend on a wide range of underlying causes and accompanying comorbidities. For this reason, management of NBD should be tailored individually with a combined multidisciplinary therapy appropriate for the status of the affected child and caregivers.
Background: Myocardial efficiency should be maintained stable under light-to-moderate stress conditions, but ischemia puts the myocardium at risk for impaired functionality. Additionally, the measurement of such efficiency typically requires invasive heart catheterization and exposure to ionizing radiation. In this work, we aimed to non-invasively assess myocardial power and the resulting efficiency during pharmacological stress testing and ischemia induction. Methods: In a cohort of n = 10 healthy Landrace pigs, dobutamine stress testing was performed, followed by verapamil-induced ischemia alongside cardiac magnetic resonance (CMR) imaging. External myocardial power, internal myocardial power, and myocardial efficiency were assessed non-invasively using geometrical and functional parameters from CMR volumetric as well as blood flow and pressure measurements. Results: External myocardial power significantly increased under dobutamine stress [2.3 (1.6–3.1) W/m2 vs. 1.3 (1.1–1.6) W/m2, p = 0.005] and significantly decreased under verapamil-induced ischemia [0.8 (0.5–0.9) W/m2, p = 0.005]. Internal myocardial power [baseline: 5.9 (4.6–8.5) W/m2] was not affected by dobutamine [7.5 (6.9–9.0) W/m2, p = 0.241] nor verapamil [5.8 (4.7–8.8) W/m2, p = 0.878]. Myocardial efficiency did not change from baseline to dobutamine [21% (15–27) vs. 31% (20–44), p = 0.059] but decreased significantly during verapamil-induced ischemia [10% (8–13), p = 0.005]. Conclusion: In healthy Landrace pigs, dobutamine stress increased external myocardial power, whereas myocardial efficiency was maintained stable. On the contrary, verapamil-induced ischemia substantially decreased external myocardial power and myocardial efficiency. Non-invasive CMR was able to quantify these efficiency losses and might be useful for future clinical studies evaluating the effects of therapeutic interventions on myocardial energetics.
The effects of exercise interventions on unspecific chronic low back pain (CLBP) have been investigated in many studies, but the results are inconclusive regarding exercise types, efficiency, and sustainability. This may be because the influence of psychosocial factors on exercise induced adaptation regarding CLBP is neglected. Therefore, this study assessed psychosocial characteristics, which moderate and mediate the effects of sensorimotor exercise on LBP. A single-blind 3-arm multicenter randomized controlled trial was conducted for 12-weeks. Three exercise groups, sensorimotor exercise (SMT), sensorimotor and behavioral training (SMT-BT), and regular routines (CG) were randomly assigned to 662 volunteers. Primary outcomes (pain intensity and disability) and psychosocial characteristics were assessed at baseline (M1) and follow-up (3/6/12/24 weeks, M2-M5). Multiple regression models were used to analyze whether psychosocial characteristics are moderators of the relationship between exercise and pain, meaning that psychosocial factors and exercise interact. Causal mediation analysis were conducted to analyze, whether psychosocial characteristics mediate the exercise effect on pain. A total of 453 participants with intermittent pain (mean age = 39.5 ± 12.2 years, f = 62%) completed the training. It was shown, that depressive symptomatology (at M4, M5), vital exhaustion (at M4), and perceived social support (at M5) are significant moderators of the relationship between exercise and the reduction of pain intensity. Further depressive mood (at M4), social-satisfaction (at M4), and anxiety (at M5 SMT) significantly moderate the exercise effect on pain disability. The amount of moderation was of clinical relevance. In contrast, there were no psychosocial variables which mediated exercise effects on pain. In conclusion it was shown, that psychosocial variables can be moderators in the relationship between sensorimotor exercise induced adaptation on CLBP which may explain conflicting results in the past regarding the merit of exercise interventions in CLBP. Results suggest further an early identification of psychosocial risk factors by diagnostic tools, which may essential support the planning of personalized exercise therapy.
Specific protocols define eligibility, conditioning, donor selection, graft composition and prophylaxis of graft vs. host disease for children and young adults undergoing hematopoietic stem cell transplant (HSCT). However, international protocols rarely, if ever, detail supportive care, including pharmaceutical infection prophylaxis, physical protection with face masks and cohort isolation or food restrictions. Supportive care suffers from a lack of scientific evidence and implementation of practices in the transplant centers brings extensive restrictions to the child's and family's daily life after HSCT. Therefore, the Board of the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT) held a series of dedicated workshops since 2017 with the aim of initiating the production of a set of minimal recommendations. The present paper describes the consensus reached within the field of infection prophylaxis.
The bile acid pool with its individual bile acids (BA) is modulated in the enterohepatic circulation by the liver as the primary site of synthesis, the motility of the gallbladder and of the intestinal tract, as well as by bacterial enzymes in the intestine. The nuclear receptor farnesoid X receptor (FXR) and Gpbar1 (TGR5) are important set screws in this process. Bile acids have a vasodilatory effect, at least according to in vitro studies. The present review examines the question of the extent to which the increase in bile acids in plasma could be responsible for the hyperdynamic circulatory disturbance of liver cirrhosis and whether modulation of the bile acid pool, for example, via administration of ursodeoxycholic acid (UDCA) or via modulation of the dysbiosis present in liver cirrhosis could influence the hemodynamic disorder of liver cirrhosis. According to our analysis, the evidence for this is limited. Long-term studies on this question are lacking.
Optimal distribution-preserving downsampling of large biomedical data sets (opdisDownsampling)
(2021)
Motivation: The size of today’s biomedical data sets pushes computer equipment to its limits, even for seemingly standard analysis tasks such as data projection or clustering. Reducing large biomedical data by downsampling is therefore a common early step in data processing, often performed as random uniform class-proportional downsampling. In this report, we hypothesized that this can be optimized to obtain samples that better reflect the entire data set than those obtained using the current standard method. Results: By repeating the random sampling and comparing the distribution of the drawn sample with the distribution of the original data, it was possible to establish a method for obtaining subsets of data that better reflect the entire data set than taking only the first randomly selected subsample, as is the current standard. Experiments on artificial and real biomedical data sets showed that the reconstruction of the remaining data from the original data set from the downsampled data improved significantly. This was observed with both principal component analysis and autoencoding neural networks. The fidelity was dependent on both the number of cases drawn from the original and the number of samples drawn. Conclusions: Optimal distribution-preserving class-proportional downsampling yields data subsets that reflect the structure of the entire data better than those obtained with the standard method. By using distributional similarity as the only selection criterion, the proposed method does not in any way affect the results of a later planned analysis.